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ABSTRACT 
 
 
Lysophosphatidic acid (LPA) is a naturally occurring lipid mediator. It exists 
abundantly in biological fluids such as serum, saliva, follicular fluid, seminal fluid and 
malignant effusions and induces a vast array of biological responses affecting cell 
growth, survival, differentiation, migration and morphology. We recently identified 
lysophosphatidic acid (LPA) as a potent antiapoptotic agent for the intestinal epithelium. 
Based on computational modeling octadecenyl thiophosphate (OTP) was synthesized: a 
novel rationally designed, metabolically stabilized LPA mimic. OTP was more 
efficacious than LPA in reducing !-irradiation-, camptothecin-, or TNF-
"//cycloheximide-induced apoptosis and caspase 3, 8 and 9 activity in the IEC-6 cell line. 
The OTP- and LPA-elicited antiapoptotic effects were completely blocked by the MEK 
inhibitor PD98059 and the PI3K inhibitor LY294002. Pertussis toxin partially abolished 
OTP-induced ERK1/2 and apoptotic protection. In RH7777 cells lacking LPA receptors, 
OTP selectively protected LPA2 but not LPA1 and LPA3 transfectants. In C57BL/6 and 
LPA1 knockout mice exposed to 15 Gy !-irradiation, orally applied OTP reduced the 
number of apoptotic bodies and activated caspase 3 positive cells but was ineffective in 
LPA2 knockouts. OTP, with higher efficacy than LPA, enhanced intestinal crypt survival 
in C57BL/6 mice but had no effect in LPA2 knockouts. Intraperitonealy administered 
OTP reduced death caused by LD100/30 radiation by 50%. Our data indicate that OTP is a 
highly effective antiapoptotic agent that engages similar prosurvival pathways to LPA 
through the LPA2 receptor subtype. 
 
Unique sequence motifs in the LPA2 carboxyl-terminal (CT) enable it to form 
macromolecular complexes with PDZ and LIM domain proteins, which link it to G 
protein-independent signaling networks. Using deletion and site-specific mutagenesis, we 
mapped out C311xxC314 motif of LPA2-CT that is required for interaction with LIM 
domain proteins thyroid hormone receptor interactive protein 6 (TRIP6) and the 
proapoptotic molecule Siva-1 in vitro and in vivo. Palmitoylation that occurs on these 
cysteine residues, however, did not affect the association with TRIP6 or Siva-1.  The 
L351A mutation in the PDZ motif weakened but did not abolish interaction with LIM 
proteins. Alanine mutation of the LIM binding motif or PDZ domain binding motif 
attenuated LPA-induced activation of the prosurvival ERK1/2 and Akt pathways in 
mouse embryonic fibroblasts (MEF) derived from LPA1 and LPA2 double knockout mice 
and reconstituted with mutants of LPA2. Neither of these mutations alone nor in 
combination had a detectable effect on G-protein-linked activation of Ca2+ mobilization.  
Triple alanine mutations modifying residues Cys311, Cys314, and Leu351 abolished the 
antiapoptotic effect of LPA. Together, these findings suggest the macromolecular 
complex formed between LPA2, TRIP6/Siva-1, and PDZ domain proteins plays an 
important role in mediating the anti-apoptotic effects of LPA2. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
 
1.1     LPA RECEPTOR AND SIGNALING 
 
 
1.1.1 LPA Receptors and Signaling 
 
Lysophosphatidic acid (LPA) is a naturally occurring lipid mediator. It is a 
prototypical member of the biological lipid family of phospholipid growth factors 
(PLGFs) including phosphatidic acid (PA), plasmologen glycerophosphate (PGP), 
sphiongosine-1-phosphate (S1P), cyclic glycerol-3-phosphate (cPA), 
sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC) (Tigyi, 2001 
review). LPA is released by platelets, adipocytes, fibroblasts, endothelial cells, cultured 
postmitotic neurons, and several types of cancer cells (Aoki, 2004 review). It exists 
abundantly in biological fluids such as serum, saliva, follicular fluid, seminal fluid and 
malignant effusions and induces a vast array of biological responses affecting cell 
growth, survival differentiation, migration and morphology (Tigyi & Parrill, 2003 
review). It functions through activation of its cognate membrane-bound receptors 
(LPARs) that belong to G protein coupled receptors (GPCR) family. LPA1-3 belongs to 
the Endothelial Differentiation Gene (EDG) family and share 50% sequence homology 
with the most divergence at the C-terminal ends (Anliker & Chun, 2004 review). 
GPR23/LPA4 (Noguchi, 2003) and GPR92/LPA5 (Kotarsky, 2006) are more closely 
related to purinergic receptors than EDG receptors. GPR87 (potential LPA6) and P2Y5 
(potential LPA7), belonging to the P2Y family, have recently been deorphanized and 
found to be LPA receptors (Shimomura, 2007; Tabata, 2007). P2Y5 has been found to be 
essential for maintenance of human hair growth (Pasternack, 2008; Shimomura, 2008). 
More interestingly, proxisome proliferators-activated receptor ! (PPAR!) has been 
identified as an intracellular receptor of LPA (McIntyre, 2003). 
 
Upon LPA stimulation, LPARs interact with different G proteins (Gs, Gi/o, Gq and 
G12/13) to activate various downstream effector pathways, which explains the diverse 
cellular effects of LPA (Mills & Moolenaar, 2003 review; Ishii I, 2004 review). LPA1 
displays robust coupling to Gi/o and G12/13 and weak coupling to Gq.  While LPA2 and 
LPA3 interact more strongly with Gq. LPA2 can also couple to G12/13. Signaling through 
Gq activates PLC, which subsequently hydrolyzes PIP2 and elicits Ca
2+ mobilization. Gi/o 
mediates inhibition of adenylyl cyclase that decreases cAMP levels. It also mediated 
stimulation of Ras-MAP kinase and PI-3-kinase/Akt pathways; G12/13 is involved in 
activation of small GTPase RhoA, which regulates actomyosin-based cytoskeleton 
contraction. Gs activates adenylyl cyclase to increase cAMP. LPA4 couples to Gs and 
Gq/Gi to mediate Ca
2+ signaling and G12/13 to mediate Rho activation (Lee, 2007). LPA5 
couples to Gq, G12/13 and G$! to activate Ca
2+, Rho and increase cAMP respectively (Lee, 
2006). Activation of P2Y5 increases cAMP (Pasternack, 2008) 
 
In adult mice, LPA1 is widely expressed with high levels in testis, brain, lung, 
heart, spleen and intestine, and moderate levels in kidney, stomach, thymus and muscle.  
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LPA2 and LPA3 are somewhat more restricted. LPA2 is generally low in most tissues 
except testis, protstate, pancreas and leukocytes. Expression of LPA3 is high in kidney, 
testis, lung and to a lesser extent in small intestine, heart, spleen, thymus and stomach 
(Anliker & Chun, 2004 review). The ratio of LPA2/LPA1 increased markedly during 
malignant transformation (Shida, 2004). LPA4 has a wide expression in embryonic and 
restricted to heart and skin in adult tissues (Lee, 2007). LPA5 has a broad low level of 
expression in many tissues with higher expression in small intestine and sensory dorsal 
root ganglion (Lee, 2006). LPA6 is expressed in genital organ system, brain and skeletal 
muscle, not in heart, lung, kidney, liver or intestine (Tabata, 2007). 
  
LPA1 knockout mice revealed that LPA1 is required for normal development of an 
inborn neonatal behavior. LPA1-/- mice resulted in 50% neonatal lethality and suckling 
impairment in neonatal pups. LPA1-/- primary cortical culture revealed loss of LPA 
responses (Contos, 2000). In contrast, LPA2 -/- mice don’t show obvious phenotypic 
abnormality (Contos, 2002).  LPA3 knockout reveals import role of LPA3 signaling in 
implantation and embryo spacing (Ye, 2005). 
 
Accumulating evidence has shown that LPA is a potent antiapoptotic factor. LPA 
protects various cell lines from apoptosis induced by different apoptotic stimuli: serum-
deprived apoptosis in fibroblasts (Fang, 2000), macrophages (Koh, 1998), T cells 
(Goetzl, 2000), Schwann cells (Weiner, 1999), renal proximal tubular cells (Levine, 
1997), intestinal epithelial cells (Deng 2002); chemotherapeutic agents-induced apoptosis 
in BJAB and I-83 B cell lines, primary chronic lymphocytic leukemia (CLL) cell lines 
(Hu, 2005), prostate cancer cells (Raj, 2004), intestinal epithelial cells (Deng, 2002), 
colon cancer cell lines (Rusovici, 2007) and ovarian cancer cell lines (Frankel 1996, 
Meng, 2005); Death receptor-induced apoptosis (Kang, 2004); radiation-induced 
apoptosis in epithelium (Deng, 2002). The apoptosis protection by LPA is mainly 
mediated by LPA1 and LPA2. ERK and/or Akt/PKB signaling pathways, among others, 
have been identified to mediate the LPA anti-apoptotic effects in most of these cell lines 
(Radeff-Huang, 2004).  
 
Our group has found that LPA protects IEC-6 cells from apoptosis induced by 
different stimuli: serum withdrawal, DNA damaging agent (camptothecin), TNF" and !-
irradiation (Deng, 2002). LPA protects IEC-6 from apoptosis through inhibition of the 
mitochondria apoptotic pathway (Deng, 2003). This survival role of LPA doesn’t involve 
transactivation of EGFR, ErbB2 or PDGFR (Deng, 2004). 
 
 
1.1.2 OTP: A Rationally Designed LPA Mimic 
 
Studies on LPA, a naturally occurring lipid with a diversity of biological function, 
have provided us with knowledge of LPA function. It would be practical to utilize these 
features of LPA to better serve the human kind. Our lab has been focusing on rational 
drug design using computational modeling and docking studies (Tigyi & Parrill, 2003 
review). In an effort to find LPAR subtype-specific agonists and antagonists that allow 
dissection of the roles of LPAR subtype functions, we have synthesized the compound 
 3 
octadecenyl thiophosphate (OTP) based on computational modeling of LPA receptor 
(Virag, 2003; Durgam, 2005). In structure, OTP lacking the glycerol backbone, consists 
of only a polar phosphate head group and a fatty acid tail. This makes OTP more resistant 
to the degradation by lipase and phospholipase. Also sulfur replacement of oxygen at the 
phosphate makes OTP a poor substrate for lipid phosphate phosphatase (LPP). However, 
this modification doesn’t interfere with either recognition or interaction with LPARs.  
These properties of OTP prompted us to explore its antiapoptotic role both in vitro and in 
vivo, due to its structure resemblance to LPA. 
 
 
1.2 APOPTOSIS IN SMALL INTESTINE EPITHELIUM 
 
Apoptosis is generally defined as the morphological end point of a complex 
signaling cascade resulting in the activation of intracellular proteases denoted as 
caspases. The process of apoptosis is the end point of an energy dependent cascade of 
events initiated by death inducing stimuli. Two distinct apoptotic pathways operate in 
mammalian cells: intrinsic and extrinsic apoptotic pathways (Fig. 1.1). The intracellular 
stimuli, like genotoxic stresses and radiation, trigger the mitochondrial pathway, in which 
release of cytochrome C from the mitochondria is the key event leading to caspase 
activation. For the extrinsic pathway, the stimuli are death ligands (TNF", Fas ligand, 
TRAIL). Apoptosis is initiated by ligand binding to death receptors (Fas, TNFR, 
interferon and TRAIL receptors) (Jin, 2005 review; Chowdhury, 2006 review). 
 
 
1.2.1 Intrinsic (Mitochondria-mediated) Apoptotic Pathway 
 
Activation of this pathway is triggered by the release of cytochrome C from 
mitochondria intermembrane space to the cytosol. The released cytochorome C binds 
APAF-1 (apoptotic protease activating factor-1) via its WD40 domain and, in the 
presence of ATP, binding of which induces conformational change and CARD (caspase 
recruitment domain) exposure of APAF-1. Usually the CARD domain of APAF-1 is 
bound by two of its WD40 domains and is exposed when cytochrome c binds to the 
WD40. Subsequently the procaspase 9 is recruited to the CARD forming a high 
molecular weight complex called apoptosome. This complex formation resulted in 
cleavage of procaspase 9 to active caspase 9, which subsequently activate down stream 
caspases, namely caspase 3 and 7. A protelytic cascade is then initiated with the cleavage 
of procaspase 2, 6, 8 and 10, leading to the dismantling of the cell (Danial & Korsmeyer, 
2004). 
 
IAPs (inhibitor of apoptosis proteins) act as endogenous caspase inhibitors by 
binding to active caspase 9 and 3, controlling the activation of effector caspases 
downstream of apoptosome. IAPs have been reported to function as an E3-ubiquitin 
ligase that targets active caspase for rapid degradation (Suzuki, 2001). In turn, IAPs are 
regulated by its antagonists: Smac/DIABLO and Omi/HtrA2, two mitochondrial IMS 
proteins released upon mitochondria outer membrane permeabilization (MOMP). These 2  
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Figure 1.1.  Apoptotic pathways. Schematic representation of the simplified apoptotic 
pathways in mammalian cells. 
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proteins bind to XIAP via an AVP (I/S) sequence at their N termini and antagonize IAP 
inhibition of caspases (Spierings, 2005 review). 
 
AIF (apoptosis inducing factor) and Endonuclease G are also released from 
mitochondria and provoke caspase–independent DNA degradation. The precise 
molecular mechanism by which apoptogenic proteins are released from mitochondria is 
still elusive. Different models have been proposed, with many implicating the MOMP. 
The mitochondria permeability transition pore (PTP), consisting of the ANT protein 
(Adenine Nucleotide Translocator), the VDAC (Voltage dependent anion channel), the 
benzodiazepine receptor, and cyclophilin D, is thought to play an important role (Bras, 
2005 review).  
 
Upstream of MOMP, Bcl2 family members are believed to be fundamental 
regulators of MOMP and subsequent release of mitochondrial factors (Spierings, 2005).  
Bcl2 gene was first discovered in human B cell lymphomas (Tsujimoto, 1987). Many 
members have been discovered and categorized into two main subfamilies: proapoptotic 
and antiapoptotic. They share at least one of four Bcl-2 homology (BH1-4) domains. The 
known antiapoptotic members include Bcl-2, Bcl-xl, mcl-1, bcl-w and A1, which show 
sequence conservation among all four domains. The proapoptotic group is further divided 
into BH1-3 and BH3-only proteins. BH1-3 proteins share three of the BH domains, 
including Bax, Bak and Bok. The BH3-only proteins are Bid, Bim, Bik, Bmf, Bad, Hrk, 
BNIP3, Noxa and PUMA. An important feature of the Bcl2 family members is the ability 
to form homo or heterodimers, suggesting the neutralization of competition between 
these proteins (Schultz, 2003 review; Shibe, 2006 review). 
 
While it is clearly elucidated that how MOMP leads to caspase activation, the 
exact mechanism that how Bcl-2 family members controls the MOMP is not known. 
Douglas R Green proposed four models for this (Green, 2006 review). The first one is 
‘death by default’ model involving the interplay of the three subfamilies of Bcl-2. In this 
model Bax and Bak are constitutively active and held in check by antiapoptotic Bcl-2 
proteins. BH3-only proteins neutralize the anti apoptotic Bcl-2 proteins, release Bax and 
Bak that have channel forming capabilities and result in MOMP. The second model is 
‘life by default’ model in which Bax and Bak are activated by the BH3-only proteins (Bid 
and Bim in this case), MOMP occurs when other BH3-only proteins neutralize 
antiapoptotic proteins. The third model proposes that neutralization of antiapoptotic Bcl-2 
proteins leads to death only in cells that have been stressed to engage the direct activators 
of Bax and Bak but are kept alive by one or more of the antiapoptotic Bcl-2 family 
member. The fourth model is that proteins like p53 and others may function like Bid or 
Bim to activate Bax and Bak or Bax and Bak can be directly activated by conditions in 
the cell without a requirement for other proteins, like detergents and mild heat (Green, 
2006 review). 
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1.2.2 Extrinsic (Death Receptor-mediated) Apoptotic Pathway 
 
The extrinsic apoptotic pathway is initiated upon ligation of death receptors by 
their cognate ligands that belong to TNF family. Death receptors belong to the TNF 
superfamily of the cell surface receptors. They contain a cytoplasmic protein motif 
termed the death domain (about 80 conserved amino acids in length) that enables death 
receptors to engage the cell’s apoptotic machinery (Nagata, 1997). These receptors are 
activated upon their ligands binding. This binding results in receptor trimerization, 
clustering of the receptors’ death domains and recruitment of adaptor molecules (e.g. Fas 
associated death domain [FADD] or TNFR associated death domain [TRADD]) through 
homophilic interaction mediated by the death domain (Chinnaiyan, 1995; Hsu, 1995). 
FADD and TRADD are adaptor proteins where different intermediates can bind and lead 
to death or survival pathway activtion. When FADD recruits pro-caspase 8 to the 
activated CD95 receptor to form the CD95 death-inducing signaling complex (DISC), 
oligomerization of pro-caspase 8 upon DISC formation drives its activation through self-
cleavage. Caspase 8 activates downstream effector caspases such as caspase 3. In some 
cell lines, if the initial caspase activity is low, activated caspase 3 can positively feed 
back to caspase 8 and reinforce its activation. 
 
 
1.2.3 Physiology of Small Intestinal Stem Cells 
 
The mammalian intestinal epithelium provides an excellent model for the study of 
cell proliferation, migration and differentiation in that it represents one of the fastest 
renewal systems. The mouse small intestine is lined by a single layer of epithelium that 
consists of flask-shaped invaginations known as crypts and finger-like luminal 
protrusions termed villi. The epithelia maintains steady state by replenishing the loss of 
cells at the tip of villus with proliferating cells derived from the stem cells at the crypts 
through migration and differentiation. There are four differentiated cell types: 
enterocytes, goblet cells, enteroendocrine cells and Paneth cells. The differentiation 
process operates by a bidirectional migration: Paneth cells migrate to the bottom of the 
crypt, while the other three types of cells upward to the tip of villi.  
 
Based on cell kinetic, lineage tracking, somatic mutation studies combined with 
complex mathematical modeling, Potten CS proposed a stem cell hierarchy organization 
in the crypt (Marshman, 2002)(Fig.1.2). This model suggests a 4-6 actual /functional 
stem cells per crypt in steady state. They are located at cell position 4-5, immediately 
above a population of fully differentiated Paneth cells. These stem cells divide 
asymmetrically. They produce a daughter cell that remains at the 4th cell position and the 
other daughter cell is displaced one cell position away. When this stem cell divides next 
time, the transit cell just above it is displaced one cell position further up the crypt. In this 
way, the stem cells maintain their number and at same time producing daughter cells that 
possess a series of cell lineage of up to six discrete cell generations. The distribution of 
cell lineage is related to its topographical position in the crypt. This model is really 
attractive for studying stem cells with the fact that there is no specific histologic or 
immunologic marker of the intestinal stem cells. If the actual stem cells die, they are  
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Figure 1.2.  Current model for the cell lineage in small intestinal crypts. The position 
of a cell in the lineage can be related to its topographical position within the tissue.  
 
Reprinted with permission from Radiation Research Society: Radiation Research. Potten 
CS. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as 
the small intestine. Radiat Res. 2004 Feb;161(2):123-36. 
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replaced by other surviving stem cells or by their immediate daughter (transit cells. The 
first three generations of transit cells around 30-40 in number are believed to be potential 
stem cells or clonogenic stem cells, while transit 4-6 generations are about 120 dividing 
cells (dividing transit cells). They don’t have stem cell attributes.  
 
 
1.2.4     Radiobiology in Mouse Small Intestinal Stem Cells 
 
 !-irradiation (!IR) is one of the typical genotoxic stresses that induce DNA 
damage and primarily results in double strand breaks (DSBs), which activate DNA 
damage checkpoints to initate signals ultimately leading to binary decision between cell 
death and cell survival. In mammals, the signal of DNA damage caused by !IR is sensed 
by sensor proteins like RAD9, RAD1, RAD17, HUS1, transduced by ATM/ATR, which 
are protein kinases that phosphorylate target effector proteins such as CHK1/CHK2. The 
well-known effector responses to DNA damage are cell growth arrest, DSB repair or 
apoptosis. Key to these complex cellular responses is the tumor suppressor p53 that has 
been recognized as an important checkpoint protein-guardian of the genome. In some 
systems, but not all, there is a close relationship between radiation–induced accumulation 
of p53, transactivation of p53 target genes and the consequent adaptive responses, 
including apoptosis. WT p53 is a short-lived protein with a rapid turnover under normal 
conditions. Upon genotoxic insult, a rapid stabilization of the p53 protein by post- 
translational modification and its activation leads to cell cycle arrest and /or apoptosis. 
The best understood player in this pathway is mdm2. The level of p53 protein 
accumulation in response to IR primarily relates to the intensity of DNA damage (Fei & 
El-Deiry, 2003 review). The dosage of IR predominately contributes to the outcomes of a 
cell fate. Apoptosis occurs in response to a high dose of IR when the damage is 
irreparable. The mechanism by which p53 mediates cell arrest and apoptosis is through 
both transcriptional and transcription-independent phenomena. p53 mediates cell cycle 
arrest in the G1/S and G2 phases of the cell cycle. In the G1/S phase, the best understood 
is the regulation of p21Waf1/Cip1. In G1, p21 negatively regulates the cyclin E/cdk2 kinase 
and cyclin D/cdk4-6. These kinases phosphorylate pRB and the related proteins p107 and 
p130 during G1. pRB in turn regulates the E2F mediated transcription required for cell 
cycle progression. When p53 is activated, p21 is activated which inhibits phosphorylation 
of pRB. With hypophosphorylated pRB, E2F remains bound to pRB and E2F couldn’t 
activate transcription, leading cell cycle arrest (Hickman, 2002 review, Harris & Levine, 
2005 review, Schuler & Green, 2005 review).   
 
A large number of genes regulated by p53 are known to regulate apoptosis: Bax, 
Noxa, Puma. By mediating these apoptotic molecules, p53 is linked to intrinsic apoptotic 
pathway. In addition, p53 regulates a series of genes that initiate the extrinsic apoptotic 
pathway (Fas ligand, killer Dr receptor), resulting activation of caspase 8. Accumulating 
data show that p53 has a transcription-independent proapoptotic function (Moll, 2005 
review). 
 
Overall a cell’s fate of cell cycle arrest, senescence or apoptosis appears to depend 
on the nature of the stress signal, the type and location of the protein modification on the 
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p53, those proteins associated with p53 and even the pattern of gene expression occurring 
in the specific tissue.  
 
Radiation has been found to be the ideal cytotoxic agent to study the cell biology 
of small intestine (Potten, 2004 review). Studies using lower dose of radiation (<1 Gy) 
revealed earlier apoptosis peaked at 3-6 h post-irradiation and there is a natural 
background level of apoptosis, which is termed spontaneous apoptosis and p53 
independent. This spontaneous apoptosis also occurs in normal human small intestine. 
These apoptotic cells always occur at cell position 4-5. The dose–response relationship 
study of these radiation-sensitive cells revealed that that there are about 4-6 apoptosis–
susceptible cells per crypt located at around cell position 4-5 and these cell lack repair 
capacity. The conclusion was drawn from these studies: the apoptotic response may be 
part of the genome protection mechanism operating on the stem cells in the small 
intestine (Potten, 2004 review).  
 
Increasing dose of radiation will kill the potential stem cells. Crypt survival curve 
drawn by counting the number of regenerating crypt-like foci at 3-4 days after different 
doses of radiation show that a large shoulder and a roughly exponential region from 
which the sensitivity of the clonogenic target cells can be determined (Fig.1.3). 8Gy will 
cause apoptotic body formation, depletion of crypt cells, and subsequent loss of the villi 
within 5-7 days, which is faster than bone marrow to show radiation effects. Higher dose 
would cause the complete sterilization of many crypts and consequent ulcers. Just one 
surviving clonogenic cell in a crypt allows its regeneration. Based on these findings a 
functional assay for quantifying stem cell survival following acute cytotoxic injury to the 
replicating cell population has been developed----Crypt Clonal Regeneration assay (the 
microcolony assay). This method involves counting the number of regenerating crypt-like 
foci between 3-4 days after different doses of radiation. These regenerating foci are easily 
recognized by routine H & E staining of paraffin-embedded sections.  
 
 
1.3     LIM AND PDZ DOMAIN PROTEINS INTERACTING WITH LPA2 C-
TERMINUS 
 
It is well known GPCR exerts their effects on cells through coupling to different 
G proteins. Recent studies reveal that GPCR also interact with cytoplasmic scaffold 
proteins, which link receptors to various downstream signaling molecules (Brady & 
Limbird, 2002 review, Hall & Lefkowitz, 2002 review; Luttrell, 2005 review). Scaffold 
proteins are defined as proteins that associate with two or more partners to enhance the 
efficiency and/or specificity of the cellular signaling pathways. There are several scaffold 
proteins have been demonstrated to interact with GPCR (Milligan & White, 2001 review; 
Hall & Lefkowitz, 2002 review). 
 
Recent studies suggest that scaffold proteins like PDZ and LIM domain proteins 
interact with LPA2 C-terminus (CT) specifically and mediate LPA2 signaling (Oh, 2004; 
Wang, 2004; Xu, 2004; Yamada, 2005; Lin, 2007; Zhang, 2007). LPA1, LPA2 and LPA3 
share high homology (>50%) in amino acid sequence except CT region, where there is 
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Figure 1.3.  Crypt survival curve.  
 
Reprinted with permission from Radiation Research Society. Potten CS. Radiation, the 
ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. 
Radiat Res. 2004 Feb;161(2):123-36. 
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only 27% identity between the LPA1 and LPA2 receptors and 17% between the LPA2 and 
LPA3.  
 
 
1.3.1 PDZ Domain Proteins 
 
PDZ domain is a modular protein-interaction domain that consists of around 90 
amino acids. It is named after the three founding PDZ containing proteins: the 
postsynaptic protein PSD-95/SAP90, the Drosophila septate junction protein Disc-large, 
and the tight junction protein ZO-1. The PDZ domain proteins bind specifically to 
distinct peptide sequences in the CT of the target proteins, most often transmembrane 
receptors and channels. Based on the sequences they recognize, three classes of PDZ 
domain proteins have been categorized (Harris & Lim, 2001 review). Class I PDZ 
domains preferentially bind to the CT motif S/T-x-%-COOH (where X= any amino acid, % 
=hydrophobic amino acid). Class II PDZ domain proteins recognize the motif %-x-%-
COOH. Class III proteins recognize x-x-C-COOH. There are also PDZ proteins that don’t 
fall into these three categories. PDZ domains also mediate signaling through PDZ-PDZ 
interaction, recognition of internal protein sequences, and phosphatidylinositol moiety 
(Harris & Lim, 2001 review; Hung & Sheng, 2002 review; Jelen, 2003 review).  
 
So far, at least four PDZ-containing proteins have been found to interact with 
LPA2: Na
+/ H+ exchange regulatory factor 2 (NHERF2) (Oh, 2004; Yun, 2005); PDZ-
RhoGEF (Yamada, 2005); leukemia-associated RhoGEF (Wang, 2004); membrane 
associated guanylate kinase-like protein with an inverted domain structure-3 (MAGI-3) 
(Zhang, 2007). The well-studied PDZ domain protein interacting with LPA2-CT is 
NHERF2. The second PDZ domain of NHERF2 interacts specifically with LPA2, but not 
LPA1 or LPA3 (Oh, 2004). Shim’s group (Yun, 2005) has found that NHERF2 regulates 
LPA2 -mediated mitogenic signals in Caco-2 cells. In collaboration with Dr. A.P. Naren, 
our group found that LPA2 receptor formed a macromolecular complex with CFTR and 
NHERF2 via the second PDZ domain. This macromolecular complex formation was 
reduced by LPA2 L351A point mutant and completely abolished by LPA2 &STL (Li, 
2005a).  
 
 
1.3.2 LIM Domain Proteins 
 
The LIM domain is named by the acronym of three homeodomain proteins: Lin-
11, Isl-1 and Mec-3. It usually consists of approximately 55 amino acids with 8 highly 
conserved residues, mostly cysteine and histidine located at defined intervals. The 
classical LIM consensus sequence has been defined as CX2CX16-23HX2 CX2 CX2CX16-21 
CX2(C/H/D) (X denotes any amino acid) (Fig.1.4). These eight highly conserved residues 
are the zinc binding residues (Fig.1.4). LIM domain proteins are found in the nucleus 
cytoplasm or shuttle between the two compartments. These proteins have been found to 
play important roles in a variety of fundamental, biological processes including 
cytoskeletal organization, cell lineage specification and organ development as well as in 
disease processes like oncogenesis. These functions are mediated by interaction with 
 12 
 
 
 
Figure 1.4.  Conserved sequence and topology of the LIM domain. (A) conserved 
sequence of LIM domains. (B) LIM domain forms two sequencial zinc-fingers. 
 
Reprinted with permission from Mcmillan Publishers Ltd: Nature Review Molecular 
Cellular Biology. Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to 
the nucleus. Nat Rev Mol Cell Biol. 2004 Nov; 5(11): 920-31. 
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proteins that have LIM domain motifs (Bach, 2000 review; Kadrmas & Beckerle, 2004 
review; Zheng, 2007).  
 
Dr. Lin’s group has found that TRIP6 (Thryoid Receptor Interacting Protein 
6)/ZRP-1 (zyxin-related protein-1) interacts with LPA2-CT, but not LPA1 and LPA3, 
using yeast two-hybrid screening and this interaction mediates LPA-dependent cell 
migration (Xu, 2004). TRIP6 was first identified by interaction with Thryoid-hormone 
receptor (Lee, 1995). It belongs to the LIM domain protein subfamily of Zyxin, which 
consists of Zyxin, LPP (lipoma preferred partner) and Ajuba (Macalma, 1996; Petit, 
2005). These members contain a divergent N-terminal domain rich in prolines, which 
has a Nuclear Exporting Signal (NES) and a C-terminal region with three LIM domains 
(Yi & Beckerle, 1998).  In resting cells the zyxin family members localize primarily at 
focal adhesion plaques (Beckerle, 1997). By associating with cytoskeleton and signaling 
proteins, they regulate actin dynamics, cell movement, and signal transduction (Wang & 
Gilmore, 2003).  Also mounting evidence shows that these zyxin members shuttle 
between the nucleus and focal adhesion plaques. In the nucleus, these proteins interact 
with various transcription factors and they have been found to have transactivation 
ability (Wang & Gilmore, 2003). 
       
TRIP6 is a protein of 476 amino acids. Physiological function of TRIP6 is still 
elusive, though many TRIP6-interacting proteins have been identified. Besides LPA2, 
TRIP6 has been found to interact with tyrosine phosphatase PTP1E/PTP-BL (Cuppen, 
2000), the v-Rel oncoprotein (Zhao, 1999), the integrin-associated adaptor protein 
p130cas, the serine/threonine RIP2 (Li, 2005b), tumor suppressor protein Scrib (Petit, 
2005), and a cellular energy sensor protein AMPK (Solaz-Fuster, 2006). The interaction 
of TRIP6 with LPA2 promotes LPA-dependent recruitment of TRIP6 to the focal 
adhesion where it interacts with focal adhesion molecules: focal adhesion kinase, 
p130cas, paxillin and c-Src. c-Src can phosphorylate TRIP6 at Tyr-55 and the 
phosphorylation mediates the LPA-induced ERK activation (Lai, 2005). Recently the 
same group found that PTPL1/FAP-1, which can dephosphorylate TRIP6 at Tyr-55, 
negatively regulates the LPA-induced morphological change and cell migration (Lai, 
2007). 
 
Interestingly to us, phosphorylation at Tyr-55 of TRIP6 by c-Src regulates LPA-
mediated ERK activation (Lai, 2005). Knockdown of TRIP6 drastically attenuates LPA-
induced ERK1/2 activation in c-Src expressing cells (Lai, 2005).  Furthermore, LPA 
activates Src and inhibition of Src abolishes its protective effect (Deng & Tigyi, 
unpublished). TRIP6 also potentiates receptor-interacting protein 2 (RIP2)-mediated NF-
'B and ERK activation (Li, 2005b). These observations suggest that TRIP6 could be 
involved in mediating the anti-apoptotic effect of LPA2 by ERK activation, which is a 
required signal for the protective effect of LPA (Deng, 2003; E, 2007).  
 
Siva-1 is another LPA2 -interacting protein with high affinity using yeast two 
hybrid screens (Lin, 2007). Siva-1 is a pro-apoptotic molecule initially discovered by 
using the cytoplasmic tail of CD27 as bait in a yeast two-hybrid screen (Prasad, 1997). 
The Siva gene is organized into 4 exons, which generates two transcripts. The full-length 
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transcript is called Siva-1, and the short one Siva-2 lacking the exon 2 coding sequence 
(Yoon, 1999). Siva-1 is not related to either death domain containing proteins like FADD 
or TNFR associated factors (TRAFs) domain proteins. Also, Siva-1 does not contain any 
Bcl-2 Homology (BH) domains. So it is not related to Bcl-2 family members. However, it 
contains two carboxyl zinc finger-like cysteine-rich domains and these cysteines are also 
present in the human and rat homologues. Overexpression of Siva-1 in various cell lines 
induced apoptosis (Prasad, 1997). Siva-1 expression is up-regulated during DNA damage 
responses (Qin, 2002; Daoud, 2003; Fortin, 2004; Jacobs 2007; Lin, 2007). More 
interestingly, the Siva-1 gene is found to be a direct transcriptional target of both p53 and 
E2F (Fortin, 2004). Siva-1 binds to Bcl-XL and inhibits Bcl-XL mediated protection 
against UV radiation-induced apoptosis (Xue, 2002). A putative amphipathic helical 
region (SAH) is found to be sufficient to bind Bcl-XL and sensitize cells to UV radiation 
induced apoptosis (Chu, 2004). The underlying mechanism involves cytochrome C 
release, activation of caspase 9 and caspase 3. In T lymphocytes, overexpression of Siva 
proteins induces apoptosis via a caspase dependent mitochondrial pathway (Py, 2004). 
Dr. Lin’s group has found that adriamycin-induced Siva-1 protein stabilization is 
attenuated by LPA in an LPA2-dependent manner, and the function of Siva-1 in 
promoting DNA damage-induced apoptosis is inhibited by LPA pretreatment. Prolonged 
LPA stimulation promotes the interaction, ubiquitination and degradation of Siva-1 with 
the LPA2 receptor. Consistent with this result, knockdown of LPA2 expression increases 
Siva-1 protein levels and augments adriamycin-induced caspase-3 activation and 
apoptosis (Lin, 2007). All these lines of evidence point to Siva-1 as proapoptotic. 
However, the mechanism of the apoptosis-promoting function of Siva-1 remains elusive. 
 
The role of Siva-1 in apoptosis and the finding of Siva-1 interaction with LPA2 
prompted us to investigate the antiapoptotic mechanism of LPA2. Amino acid alignment 
of LPA2-CT with TRIP6 and Siva-1 display highly conserved cysteine residues in LPA2-
CT. Since zinc-finger mediates protein-protein interaction, we hypothesize that these 
cysteine residues may constitute the binding motif of LPA2 to TRIP6 and/or Siva-1 
(Feuerstein, 1994; Schmeichel & Beckerle, 1994; Arber & Caroni, 1996).  
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CHAPTER 2. THE LYSOPHOSPHATIDIC ACID TYPE 2 RECEPTOR IS 
REQUIRED FOR PROTECTING AGAINST RADIATION-INDUCED 
INTESTINAL INJURY* 
 
 
2.1     INTRODUCTION 
 
The stem cells of the intestinal mucosa represent one of the most radiation-
vulnerable cell types in the mammalian body (Potten, 2004). Whereas free radical 
scavengers can ameliorate the central nervous system syndrome and the widely used bone 
marrow transplant can effectively treat the hematopoietic syndrome caused by exposure 
to lethal doses of radiation, effectively treating the gastrointestinal syndrome due to 
radiation-induced apoptosis of the intestinal stem cells is more difficult.  
 
Lysophosphatidic acid (1-radyl-2-hydroxy-sn-glycero-3-phosphate, LPA) is a 
growth factor-like lipid mediator with antiapoptotic actions elicited through a set of G 
protein-coupled receptors (GPCR) (Tigyi & Parrill, 2003; Moolenaar, 2004). At least five 
LPA GPCRs have been identified so far (Ishii, 2004). The LPA1, LPA2, and LPA3 
receptors are encoded by the endothelial differentiation gene (EDG) family and share 
approximately 60% identity to each other (Tigyi & Parrill, 2003; Ishii, 2004). LPA4 and 
LPA5 are distantly related to these LPA receptors of the EDG family, share only 20-24% 
amino acid identity with the EDG family, and functionally are less well characterized 
(Noguchi, 2003; Kotarshy, 2006; Lee, 2006). The mouse intestine predominantly 
expresses the LPA1 and LPA2 receptor subtypes(Li, 2005; Yun, 2005). Each individual 
LPA receptor has its distinct coupling pattern to G proteins. LPA1 couples to Gi and 
G12/13; LPA2 couples to Gi, Gq, and G12/13; while LPA3 couples to only Gi and Gq, but not 
G12/13 (Ishii, 2000). These G proteins share many downstream signaling pathways that act 
in a cooperative manner (Yart, 2002). The activation of the phosphoinositide-3-kinase 
(PI3K)-AKT and MEK-ERK1/2 prosurvival pathways has been well delineated in 
mediating LPA-initiated antiapoptotic activity (Deng, 2002; Ye, 2002; Deng, 2003). LPA 
activates AKT, which in turn phosphorylates BAD and procaspase 9 leading to inhibition 
of apoptosis (Kang, 2004). LPA-induced activation of MEK-ERK1/2 signaling can also 
activate BAD phosphorylation and attenuate caspase 9 (Fang, 1999). LPA has been 
shown to activate NF'B, which regulates important prosurvival genes (Fang, 1999; 
Chou, 2005). A specific cellular response, including the antiapoptotic effect of LPA, 
might be mediated through a single LPA receptor or a combination of multiple receptors 
subtypes, which appear to be co-expressed in most cell types (Fischer, 1998). Because 
LPA receptors are ubiquitously expressed and because of the overlapping coupling  
 
 
* Adapted by permission: Shuyu E#, Wenlin Deng# (# contributed equally), Ryoko 
Tsukahara, William J. Valentine, Gangadhar Durgam, Veeresa Gududuru, Louisa Balazs, 
Venkatraman Manickam, Marcello Arsura, Lester VanMiddlesworth, Leonard R. 
Johnson, Abby L. Parrill, Duane D. Miller, and Gabor Tigyi. The Lysophosphatidic Acid 
Type 2 Receptor is Required for Protection Against Radiation-Induced Intestinal Injury. 
Gastroenterology 2007;132:1834-1851. 
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patterns to G proteins, elucidating the biological responses mediated by each individual 
receptor requires targeted gene knockout animal models. LPA1, LPA2, and LPA1/LPA2 
double knockout (KO) animals have been generated and show minimal phenotypes 
(Contos, 2000; Contos, 2002; Ye, 2005). At the present time, it remains unknown which 
LPA receptor(s) is required for its antiapoptotic effect in the different organs. 
 
LPA in the GI tract comes from foods such as soybean (Chevreau, 1995; Funk-
Archuleta, 1997; Logvinova, 1999), metabolism of phospholipids by phospholipases 
(Sturm, 2002), or activated platelets under pathological conditions (Sano, 2002). High 
levels of phospholipids have been detected in the colonic mucosa of patients with 
inflammatory bowel disease, and LPA significantly reduces the degree of inflammation 
and necrosis in a rat model of colitis (Sano, 2002). LPA has been shown to stimulate 
restitution of intestinal epithelia via pertussis toxin (PTX)-sensitive mechanisms (Hines, 
2000). LPA2 receptors play an important attenuating role in bacterial toxin-induced 
secretory diarrhea via PDZ-domain-mediated protein-protein interactions inhibiting the 
activation of the CFTR Cl- channel (Li, 2005a). Therefore, the food-derived LPA in the 
lumen and its receptors on the epithelium suggest a physiological role for LPA in 
maintaining GI integrity that can be explored for therapeutic intervention. 
 
Apoptosis in the intestinal epithelium is the primary pathological factor that leads 
to chemotherapy- or radiation-induced gastrointestinal damage (Hall, 1994; Pritchard, 
1996; Potten, 2004). We formulated a hypothesis that LPA can be used for the protection 
of the mucosa from iatrogenic traumas—radiation injury in particular—and, if so, it could 
serve as a template for prosurvival drugs against radiation injury. This hypothesis is 
based on several lines of our work reported over the last few years. We demonstrated that 
LPA protected intestinal epithelia against irradiation-induced apoptosis both in vitro and 
in vivo (Deng, 2002), also showed  that LPA achieved its antiapoptotic effects through 
the PTX-sensitive activation of the MEK-ERK1/2 and PI3K-AKT prosurvival pathways 
(Deng, 2003), and established that the antiapoptotic effect, unlike the mitogenic and 
motogenic effects of LPA, did not require the transregulation of several tyrosine kinase 
receptors (Deng, 2004). However, LPA is not an optimal drug candidate. Exogenous LPA 
is rapidly metabolized in the GI tract. Because complex lipids, including phospholipids, 
are broken down to nonpolar intermediates that traverse the plasma membrane, LPA’s 
action is terminated by phospholipase- and lipase-mediated deacylation or (lipid) 
phosphatase-mediated dephosphorylation. While this mechanism rapidly renders LPA 
inactive, it also limits LPA’s effect to the receptors present on the luminal surface of the 
epithelium. LPA consists of a glycerol backbone with a hydroxyl group, a phosphate 
group, and a fatty acid or fatty alcohol chain. We have developed and experimentally 
validated computational models of the EDG family of LPA receptors (Parrill, 2000; 
Wang, 2001; Sardar, 2002; Parrill, 2004; Fujiwara, 2005; Inagaki, 2005; Jo, 2005), and 
established the absolute requirement for a negatively charged headgroup and the aliphatic 
tail, but not for the glycerol backbone (Sardar, 2002; Virag, 2003; Durgam, 2005). 
Therefore, we hypothesized that long chain fatty alcohol thiophosphates mimic LPA at 
the EDG family receptors and at the same time are metabolically stabilized against 
phospholipase cleavage, which requires a glycerol backbone. Furthermore, 
thiophosphates tend to be poor substrates of lipid phosphatases, rendering them resistant 
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to breakdown. These observations led us to explore the pharmacological and biological 
properties of octadecenyl thiophosphate (OTP) as an orally bioavailable, metabolically 
stabilized, nonabsorbing LPA mimic with radioprotective action in the gut. 
 
The present study set multiple objectives. First, we explored the pharmacological 
properties of OTP by using computational and pharmacological approaches and 
determined its resistance to lipase and lipid phosphatase cleavage. Next, we compared the 
antiapoptotic effect of OTP to that of LPA in IEC-6 cells in vitro. Third, using a receptor 
add-back we examined which LPA receptor subtypes mediate survival signals to prevent 
radiation-induced apoptosis. Fourth, we examined whether orally applied OTP reduces 
radiation-induced apoptosis and caspase 3 activation and increases crypt survival in 
clonogenic assays conducted in C57BL/6 mice exposed to 15 Gy !-irradiation. We also 
evaluated the OTP- and LPA-induced activation of those prosurvival signaling pathways 
in vivo that we had previously established in vitro. Finally, we tested whether 
intraperitoneal administration of OTP prevents death caused by LD100/30 !-irradiation. We 
found that OTP mitigated radiation-induced death, protected intestinal epithelial cells 
from apoptosis in vitro and in vivo, and was significantly more effective compared to 
LPA. Both LPA and OTP reduced apoptosis and caspase 3 activation and increased crypt 
survival in wild type and LPA1 knockout mice; however, both were ineffective in LPA2 
knockout mice. Together, these data suggest that OTP is a highly effective intestinal 
radioprotective agent that targets LPA2 as a prosurvival receptor. 
 
 
2.2     MATERIALS AND METHODS 
 
 
2.2.1 Reagents  
 
LPA18:1 (oleoyl) was purchased from Avanti Polar Lipids (Alabaster, AL). LPA 
and OTP (synthesized as described in (Durgam, 2005) were applied to cells complexed 
with fatty acid-free BSA (Sigma, St. Louis, MO) as previously described (Virag, 2003). 
Camptothecin and cycloheximide (CHX) were purchased from Sigma. Recombinant rat 
TNF-" was purchased from BD Pharmingen (San Diego, CA). PD98059 and PD158780 
were purchased from Calbiochem (San Diego, CA). Pertussis toxin (PTX), AG1296, 
AG1487, Ac-DEVD-pNA and Ac-LEHD-pNA colorimetric and Ac-IETD-AFC 
fluorescent caspase substrates were from Biomol Laboratories Inc., (Plymouth Meeting, 
PA). The following antibodies and sources were used: rabbit anticaspase 3 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), rabbit antiactive caspase 3 (Abcam, Inc., 
Cambridge, MA), mouse monoclonal anti-JNK1 (BD Pharmingen), and mouse 
monoclonal anti-phospho (Thr183/Tyr185)-JNK; rabbit anti-ERK1/2 and rabbit anti-
phospho-(Tyr202/Tyr204) ERK1/2, rabbit anti-AKT, and rabbit anti-phospho-(Ser473)-
AKT, , rabbit anti-Bcl-2, monoclonal mouse anti-Bcl-XL (Cell Signaling, Inc., Beverly, 
MA), monoclonal mouse anti-phospho-(Thr180/Tyr182)-P38 (Promega, Madison, WI), and 
mouse monoclonal anti-actin (Calbiochem). Horseradish peroxidase-conjugated anti-
rabbit and anti-mouse secondary antibody used for Western blotting was purchased from 
Sigma. FITC-labeled goat anti-rabbit IgG was purchased from Molecular Probe (Eugene, 
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OR). Normal goat serum and VECTASHIELD Mounting Medium with DAPI were 
purchased from Vector Laboratories, Inc. (Burlingame, CA). 
 
 
2.2.2 Computational Modeling  
 
The detailed methods used to develop computational models of LPA1, LPA2, and 
LPA3 have been published previously (Wang, 2001; Sardar, 2002; Fujiwara, 2005). 
Briefly, our validated model of the S1P1 receptor (Parrill, 2000; Wang, 2001; Inagaki, 
2005) was used as a template for generating LPA receptor models. Homology model 
development was performed using the automated algorithm implemented in the MOE 
software program (MOE, 2002). The best model was geometry optimized using the 
MMFF94 (Halgren, 1996) forcefield to a root mean square gradient of 0.1 kcal/mol"Å. 
The individual receptor models were used in docking studies with OTP bearing a total 
charge of -2. Docking calculations were performed using Autodock 3.0 software (Morris, 
1998) with default values for all parameters except the number of runs (Ishii, 2000), 
energy evaluations (9.0 x 1010), generations (60,000), and local search iterations (3000). 
The complex chosen as the best geometry from each docking calculation was that with 
the lowest final docked energy value. Results are described using a numbering system 
that facilitates comparisons among homologous positions in G protein-coupled receptors 
as described by Ballesteros and Weinstein (Ballesteros, 1995). In this system, each amino 
acid in the transmembrane domain is given a number in the format X.YY where X 
indicates the number of the helix where the amino acid is found and YY indicates the 
position relative to the most conserved amino acid in that helix at reference position 50. 
 
 
2.2.3 Radiolabeling of OTP 
 
Tritiated OTP was synthesized in our laboratory as shown in Fig. 2.1D. 
Pyridinium chlorochromate-mediated oxidation of oleyl alcohol gave oleyl aldehyde, 
which was subjected to reduction with NaB3H4 to form the tritiated oleyl alcohol. 
Alcohol 3 was phosphorylated as reported earlier (Durgam, 2005) to give protected oleyl 
thiophosphate ester. Treatment of 4 with methanolic KOH followed by acidification 
yielded [3H]-OTP. The specific activity of the product was 10.8 mCi/mmol. 
 
 
2.2.4 Determining OTP Absorption from the Gut 
 
To determine oral absorption of OTP, female 8- to 10-week-old C57BL/6 mice 
(average body weight 20 g) were used. Mice were maintained on a 12:12-h light-dark 
cycle and fed standard laboratory mouse chow and water ad libitum. Conscious mice 
were administered through oral gavage 1.5 mg/kg OTP in 1 mM BSA in PBS including 
106 dpm OTP. Groups of four mice were sacrificed after 30 min, 90 min, and 180 min, 
and blood samples were collected through cardiac puncture using 0.2% EDTA anti-
coagulant. Ten microliters whole-blood samples from each mouse were mixed with  
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Figure 2.1.  Structure, computational modeling and synthesis of OTP. Chemical 
structures of LPA and OTP (Panel A). Molecular models of OTP docked into the ligand 
binding pocket of LPA receptors (Panel B). Ca2+ transients elicited by OTP and LPA in 
RH7777 cells stably expressing the individual EDG family LPA receptors (Panel C). 
Wild type RH7777 cells show no Ca2+ transients in response to LPA up to concentrations 
as high as 10 !M (data not shown). Synthesis of 3H-labeled OTP (Panel D, see 2.2 
Materials and Methods for detail). 
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Ecolume (Packard, Boston, MA) liquid scintillation cocktail and counted after 24 h of 
equilibration in a liquid scintillation counter. 
 
 
2.2.5 Assaying OTP Metabolism by Pancreatic Lipase and Lipid Phosphate 
Phosphatase 1 (LPP1) 
 
To determine the enzymatic stability of OTP by phospholipases, [3H]-OTP (5.2 x 
106 dpm) mixed with 0.03 mM cold OTP was subjected to enzymatic hydrolysis for 24 h 
by using bovine pancreatic lipase (Sigma) followed by thin-layer chromatography (TLC) 
separation of the products using a previously established protocol (Kates, 1988). Lipid 
phosphate phosphatase was obtained from mouse embryonic fibroblasts derived from 
mice with transgenic overexpression of the enzyme (Yue, 2004).  Membrane fractions 
(300 !g/reaction) prepared by centrifugation at 104 x g from transgenic LPP1 fibroblasts 
were added to [3H]-OTP (1.5x106 dpm) mixed with 8 !mole cold OTP was subjected to 
LPP-1 hydrolysis for 8 h using a previously established protocol (Yue, 2004)).  The 
reaction mixture was dried in vacuo and the residue was acidified with 100 !l 1 N HCl 
and extracted four times with 0.5 ml ethyl acetate.  The extracts were combined and the 
solvent was evaporated.  The extracted reaction products were taken up in 2 ml ethyl 
acetate and a 20 !l aliquot was applied to TLC using methanol: ether solvent (2:98. V/V) 
as described (Kates, 1988). 
 
 
2.2.6 Cell Culture and Induction of Apoptosis In Vitro 
  
IEC-6 and the rat hepatoma RH7777 cells were obtained from the American Type 
Culture Collection (Manassas, VA). IEC-6 cells were grown in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal bovine serum, insulin (10 !g/ml), and 
gentamicin sulfate (50 !g/ml) at 37 °C in a humidified 90% air/10% CO2 atmosphere. 
RH7777 cells, stably expressing LPA2 receptors, were provided by Dr. Fumikazu 
Okajima (Gunma University, Japan). RH7777 cells stably expressing LPA1 or LPA3 
receptors were generated by our group and characterized elsewhere (Fischer, 2001). Wild 
type and stably transfected RH7777 cells were grown in Dulbecco’s modified Eagle’s 
medium with 10% fetal bovine serum and 2 mM glutamine containing 250 !g/ml G418 
for the stable transfectants. Apoptosis in IEC-6 cells was induced by exposing them to 20 
!M camptothecin or a 25-Gy Cs137 source #–irradiation (Mark I model 25 Gamma 
Irradiator, J. L. Shepherd & Associates, San Fernando, CA) at a rate of 4.80 Gy/min. 
DNA fragmentation and caspase 3 activity were measured 6 h after camptothecin 
treatment or 18 h post-irradiation. Apoptosis in RH7777 cells was induced by 20 ng/ml 
TNF-$ plus 10 µg/ml CHX and evaluated 6 h later. 
 
 
2.2.7 Pharmacological Characterization of OTP 
 
The ligand properties of OTP were evaluated using RH7777 cells stably 
transfected with each LPA receptor of the EDG family exactly as described in our 
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previous report (Durgam, 2005). RH7777 cells lack endogenous Ca2+ responses to LPA 
applied as high as 30 !M, the highest concentration tested but acquire these responses 
upon transfection of any of the LPA receptors (Fischer, 2001; Virag, 2003; Durgam, 
2005;). Briefly, RH7777 cells stably expressing human LPA1, LPA2, or LPA3 were 
loaded with Fura-2 AM (Invitrogen). Changes in intracellular Ca2+ concentration were 
monitored by measuring the ratio of emitted light intensity at 520 nm in response to 
excitation by 340 nm and 380 nm wavelength lights, respectively using a FlexStation II 
(Molecular Devices, Sunnyvale, CA) robotic fluorescence plate reader. Responses were 
monitored for 70 seconds. Ca2+ transients were quantified automatically by calculating 
the difference between maximum and baseline ratio values for each sample run in 
triplicate. 
 
 
2.2.8 RT-PCR   
 
RNA was extracted using Trizol( (Invitrogen, Carlsbad, CA) from wild type and 
KO mice using four 0.5-cm segments spaced equally along the jejunum.  The following 
gene-specific primers were used: LPA1, forward, 5’- TCTGAAGACTGTG 
GTCATTGTGC-3’, reverse, 5’-GCCATTAGGGTTCTCGTTGC-3’, LPA2, forward, 5’-
CACTCCTGGCACT GCCTCTGTG-3’, reverse, 5’-TAC GGC GCA TCT CAG CGT 
CTC G-3’, LPA3, forward, 5’- ACACATGTCAATCATGAGGAT-3’, reverse, 5’-GAA 
GACGGTGACTGTCTTAGG -3’, LPA4, forward, 5’-GAAGGCTTCTCCAAACGT 
GTCTG-3’, reverse, 5’-C CTTG TGCCTTGCAACTCTGAA-3’, LPA5, forward, 5’- 
CTGATGCTC ATCAACGTGGACC-3’, reverse, 5’-TAGGGCACGAAGCACAGCAG-
3’, $-actin, forward, 5’-GACAACG GCTCCGGCATGTG-3’, reverse, 5’-TTGAGACCT 
TCAACACCCCAGCA -3’. Reverse-transcription and PCR was done using the 
Superscript III kit (Invitrogen) and a total of 31 cycles were performed; the products were 
applied in full to agarose gels and stained with ethidium bromide. 
 
 
2.2.9 Evaluating Apoptosis by DNA Fragmentation and Caspase Activity  
 
DNA fragmentation was measured by ELISA following the procedure provided 
with the Cell Death Detection kit from Roche, Inc. (Indianapolis, IN) as described 
previously (Deng, 2002 & 2003) and was expressed as absorbance units (at 405 nm) per 
microgram protein per minute. Caspase 3 and caspase 9 activity in IEC-6 cells was 
measured by ELISA by using the specific Ac-DEVD-pNA chromogenic substrate (for 
caspase 3) and Ac-LEHD-pNA for caspase 9 as described previously ((Deng, 2002 & 
2003). Small intestine samples were washed thoroughly with PBS, scraped off the muscle 
layer, mixed with lysis buffer, homogenized, and centrifuged. The supernatants were 
collected for evaluating caspase 3 activity as described above. Caspase 3 and 9 activity 
was expressed as picomole pNA cleaved per minute per microgram protein. Caspase 8 
activity was measured by using the specific Ac-IETD-AFC fluorescent substrate. Each 
reaction contained 20 !l cytosolic proteins, 70 !l assay buffer (50 mM HEPES, pH 
7.4), 100 mM NaCl, 10 mM DTT, and 1 mM EDTA and 0.1% (V/V) CHAPS detergent), 
and 10 !l of 2 mM Ac-IETD-AFC dissolved in assay buffer. The enzymatic reaction was 
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carried out in 96-well plates at 37°C and monitored using a FlexStation II microplate 
reader (Molecular Devices) at 37°C with fluorescence excitation at 405-nm and emission 
at 505-nm. Protein concentration was measured by using the Bradford protein assay kit 
(Bio-Rad, Hercules, CA), and caspase 8 activity was expressed as arbitrary fluorescence 
units (AFU)/mg/min. 
 
 
2.2.10 Western Blotting  
 
Caspase 3 was measured in IEC-6 cells or intestinal epithelial lysates prepared for 
caspase 3 activity as described in our previous reports (Deng, 2002 & 2003). ERK1/2 and 
AKT were measured in total cellular protein lysates by using a previously described 
procedure (Deng, 2003). Briefly, IEC-6 cells were lysed in 62.5 mM TRIS-HCl (pH 6.8), 
2% SDS, 25% glycerol, 1 mM NaF, 1 mM orthovanadate, and protease inhibitor cocktail 
(Sigma). The lysates were cleared by centrifugation (106 x g) for 15 min at 4°C, and 
supernatants were collected. Protein concentrations were determined using the BCA 
reagent kit (Pierce Biotechnology, Inc., Rockford, IL). For ERK1/2 10 !g, for AKT 40 
!g, for p38 20 !g, and for JNK 50 !g of the cell lysate was fractionated by SDS-PAGE 
and transferred to PVDF membranes, blocked with 5% nonfat milk, and incubated with 
various primary antibodies. Blots reacted with the appropriate HRP-conjugated secondary 
antibodies and developed using the SuperSignal chemiluminescence reagent (Pierce 
Biotechnology, Inc.). 
 
For Western blotting of Bcl-XL and Bcl-2, IEC-6 cell were harvested and washed 
with PBS twice, then resuspended with 100-200 !l ice-cold lysis buffer (20 mM TRIS 
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, protease inhibitor and 
phosphatase inhibitor cocktails (Sigma)). Cells were sonicated three times for three 
seconds each and the lysate was centrifuged at 16,100 x g for 20 min at 4°C. The 
supernatants were collected. Protein concentration was measured by using the BCA 
protein assay kit (Pierce). 
 
 
2.2.11 Animal Treatment and Irradiation 
 
The whole-body irradiation protocol was reviewed and approved by the 
University of Tennessee Health Science Center Animal Care and Use Committee. Eight 
to 10-week-old C57BL/6 mice were purchased from Harlan (Indianapolis, IN) and 
maintained on a 12:12-h light-dark cycle and fed standard laboratory mouse chow and 
water ad libitum. LPA1 and LPA2 KO mice generously provided by Dr. Jerold Chun 
(Scripps Institute, La Jolla, CA) were bred in house and used between the ages of 8 and 
12 weeks. Mice were fasted overnight before whole-body #-irradiation (Cs137 source at a 
rate of 4.80 Gy/min). LPA or OTP was administered by oral gavage 2 h before 
irradiation. Mice were killed either 4 h after irradiation by isoflurane inhalation for 
analysis of apoptosis or 4 days later for the clonogenic assay. Four segments of the 
jejunum and the ileum were fixed in 10% neutralized formaldehyde (pH 7.4) buffer and 
processed for histological evaluation. Mice used in the clonogenic regeneration assay 
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received bromo-deoxyuridine (BrdU, 120 mg/kg) and 5-fluoro-2'-deoxyuridine (12 
mg/kg) intraperitoneally 2 h before death to label the S-phase regenerating cells in 
intestine. 
 
 
2.2.12 Testing the Acute Toxicology of OTP 
  
Female eight-week-old C57BL/6 mice (average body weight 20 g) were 
maintained on a 12:12 h light-dark cycle and fed standard laboratory mouse chow and 
water ad libitum. Mice were randomly grouped into groups of 5 and weighed daily before 
oral gavage of 3, 10, and 30 mg/kg OTP dissolved in 1 mM BSA in PBS. Mice were 
observed for an hour immediately after OTP treatment and any abnormal behavior and 
change in regular motor activity was recorded. Weights were monitored for five 
consecutive days after OTP treatment. 
 
 
2.2.13 Assessing Apoptosis and Crypt Survival in Intestine  
 
Paraffin cross-sections were cut perpendicular to the long axis of the small 
intestine and stained with hematoxylin and eosin (H&E) or immunostained with a 
monoclonal anti-BrdU antibody. Epithelial cell apoptosis and crypt survival were 
analyzed in four sections per segment as previously described (Deng, 2002). To detect 
apoptosis, a minimum of 100 half crypt-villus units from each experimental group was 
scored. For the clonogenic assay, the number of surviving crypts per jejunal 
circumference was counted in the sections from the different segments. A surviving crypt 
was defined as a regenerative crypt that contained a cluster of 10 or more H&E-stained 
cells. The viability of surviving crypts was confirmed by positive immunostaining for 
BrdU of incorporation into five or more crypt cells.  
 
 
2.2.14 Immunohistological Staining 
 
To identify the BrdU-labeled S-phase cells in the crypts, we used a staining 
protocol described in our previous paper (Balazs, 2001). For activated caspase 3 staining, 
formalin-fixed paraffin-embedded tissue slides were used with heat-mediated antigen 
retrieval for 15 min. After three 5-min washes in TRIS-buffered saline (TBS, 25 mM 
TRIS, 150 mM NaCl pH 7.6), slides were blocked with 10% normal goat serum in 
TBS/0.1% Tween for 2 h at room temperature. Rabbit active caspase 3 antibody was 
diluted 1:50 in 1% BSA/TBS/0.1% Tween and incubated at 4°C overnight. FITC-labeled 
goat anti-rabbit IgG was applied for 2 h after wash, the slides were mounted with 
VECTASHIELD with DAPI (Vector Laboratories) and visualized by Nikon Eclipse 80i 
fluorescence microscope. At least 100 villi per animal were counted for the presence of 
activated caspase 3 positive cells. 
 
Immunohistochemical staining for Bcl-XL and Bcl-2 was done using 5-µm thick 
sections cut from formalin-fixed, paraffin-embedded blocks of jejunum and ileum taken 4 
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h after irradiation from a total of six mice. Upon antigen unmasking, immunostaining 
with primary antibody (1:25 dilution) was performed using the rabbit Vectastain ABC 
Elite kit (Vector Laboratories) following the manufacturer’s instructions. Vector 3,3'-
diaminobenzidine peroxidase substrate (Vector Laboratories) was used for color 
development. Stained sections were then dehydrated and counterstained with Vector 
Hematoxylin QS (Vector Laboratories), and immunoreactivity was assessed by at least 
two investigators. 
 
 
2.2.15 Monitoring the Radiation-Mitigating Effect of OTP on Survival 
 
Conscious eight-week-old female mice were injected with 0.5 mg/kg OTP or 
vehicle (2% DMSO-PBS) 30 min before irradiation with 9 Gy (LD100/30) of !-
irradiation as described above. Each group consisted of 18 mice that provide 90% 
statistical power based on a Fisher’s exact test with a one-sided 5% significance level. 
The primary endpoint was survival to day 30. The secondary endpoint was the mean 
survival time of decedents.  
 
 
2.2.16 Statistical Analysis 
 
Data are expressed as means ± SD or SEM. Each in vitro experiment was 
repeated at least three times. For animal studies, each experimental group consisted of at 
least six mice; a minimum of eight KO mice was used per group. Student's t-test was 
used for comparing control and treatment groups. A p value of <0.05 was considered 
significant.  
 
 
2.3     RESULTS 
 
 
2.3.1 Molecular Modeling and Pharmacological Characterization of OTP  
 
Complexes of OTP with the LPA receptor models are shown in Fig. 2.1B. The 
LPA1 complex shows a strong ionic interaction between the thiophosphate group and 
R3.28 (2.0 Å P-O:H-N distance). No interaction occurs involving Q3.29, a residue 
required for LPA binding and LPA-induced LPA1 receptor activation (Wang, 2001). 
Similar to the LPA1 complex, the LPA3 complex fails to show a strong hydrogen bonding 
interaction with Q3.29 due to the unfavorably nonlinear angle (Steiner, 2002) formed by 
the amide N-H and the hydrogen bond acceptor (112°). However, a greater number of 
strong ionic interactions are observed in the LPA3 complex involving not only R3.28 but 
also K7.35 (2.2 % P-O:H-N and 2.4 % P-S:H-N distances, respectively). In contrast to our 
previous studies demonstrating a role for R5.38 in LPA-induced LPA3 activation 
(Fujiwara, 2005), OTP failed to interact with R5.38. The failure of OTP to interact with 
residues known to be required for LPA-induced activation of LPA1 and LPA3 is 
consistent with the observation of only partial agonism at these receptors (Fig. 2.1C). 
 25 
OTP shows both strong ionic interaction with R3.28 (1.6 Å P-O: H-N distance) and 
moderate hydrogen bonding interaction with Q3.29 (142°). This hydrogen bonding angle 
is within the most highly populated cluster of angles observed in crystal structures ( 
Steiner, 2002). The LPA2 receptor lacks cationic amino acid residues at the top of TM7, 
so these two interactions comprise the required headgroup interactions for full agonism.  
  
LPA and OTP activate LPA receptors stably expressed in RH7777 cells, 
providing a simple assay platform to study the pharmacological properties of these 
receptors as described in many previous reports (Fischer, 2001; Ohta, 2003; Virag, 2003; 
Durgam, 2005). OTP was compared in wild type, LPA1, LPA2, and LPA3-transfected 
RH7777 cells using Ca2+ mobilization as a measure of receptor activation (Fig. 2.1C). 
OTP was inactive in wild type RH7777 cells up to 30 !M, the highest concentration 
tested (data not shown). However, it activated all three EDG-family LPA receptors with 
varying potency and efficacy. OTP was always less potent than oleoyl LPA at all three 
receptors and was less efficacious at LPA1 and LPA3 receptors. At the LPA2 receptor 
subtype OTP was a full agonist and showed an apparent EC50 of 90 nM compared 1 nM 
for oleoyl LPA. Thus, OTP is a less efficacious full agonist of the LPA2 receptor subtype. 
 
 
2.3.2 Metabolic Resistance of OTP to Pancreatic Lipase and Lipid Phosphate 
Phosphatase 1  
 
The two major pathways of LPA breakdown include (phospho) lipase-mediated 
deacylation and lipid phosphate phosphatase-mediated dephosphorylation (Brindley, 
2002). To determine the enzymatic stability of OTP by pancreatic lipase and LPP1 we 
synthesized [3H]-OTP for monitoring the enzymatic hydrolysis followed by TLC 
separation of the products using previously established protocol (Kates, 1988; Yue, 
2004). TLC analysis of the pancreatic lipase-mediated hydrolysis of [3H]-OTP for up to 
24 h showed neither the breakdown nor formation of the expected [3H]-oleyl alcohol 
(data not shown). In contrast, LPA was fully metabolized under these conditions. The 
lack of cleavage is consistent with the requirement for the glycerol backbone that is 
absent in the OTP structure. LPP1 cleavage of [3H]-OTP for up to 8 h showed no 
detectable dephosphorylation, indication that the thiophosphate moiety is considerably 
more resistant to cleavage by this enzyme than the phosphate moiety present in LPA. 
 
 
2.3.3 Absorption of Orally Applied OTP into the Blood   
 
The absorption of orally administered OTP into the bloodstream was determined 
by injecting 106 dpm [3H]-OTP tracer mixed with cold OTP to yield 1.5 mg/kg into the 
stomach. Blood samples collected at 60, 90, and 180 min later revealed that as little as 
0.67% ± 0.15, 0.61% ± 0.2, and 0.45% ± 0.15 of the applied radioactivity appeared in the 
blood compartment. Assuming that all of it was non-metabolized OTP, this would yield a 
maximal blood concentration of 180 nM, which could activate LPA receptors. However, 
TLC analysis of the radioactively labeled compounds extracted from blood revealed no 
more than 0.01% of the injected material at the position of the authentic [3H]-OTP 
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standard, indicating that the little amount of radioactivity represents metabolites of the 
compound. The very low amount of [3H]-OTP found in the blood after oral 
administration is reinforced by the lack of metabolism by pancreatic lipase and LPP1 
present in the intestinal lumen, since these enzymes would produce the neutral oleyl 
alcohol, which could more effectively be taken up than a charged compound like OTP. 
 
 
2.3.4 Orally Applied OTP Is Non-toxic in the Effective Dose Range  
 
We tested OTP applied through oral gavage into the stomach of mice at 3, 10 and 
30 mg/kg complexed in 1 mM BSA in PBS. Observation of the animals for 1 h after 
administration did not reveal any noticeable change in behavior and motor activity. 
Monitoring the weight-gain curves of the animals showed only a 24-h transient weight 
drop amounting to a mean of 3 g and only in the 30 mg/kg treatment group, but these 
animals rebounded by the second day and the median weight of the group was not 
significantly different from the vehicle treated controls beyond that up to 5 days the time 
the weight of the animals was followed daily. Thus, OTP showed no serious side effects 
even when administered at a 60-fold higher concentration — the highest dose tested so 
far — than the 0.5 mg/kg, which was highly effective in protecting the life of animals 
from lethal doses of irradiation (see below). 
 
 
2.3.5 OTP Surpasses the Antiapoptotic Activity of LPA in IEC-6 Cells 
 
We previously showed that LPA protects intestinal epithelial cells from apoptosis 
induced by four different mechanisms (Deng, 2002, 2003 & 2004). We compared the 
antiapoptotic effect of OTP with that of LPA. Although both OTP and LPA dose- 
dependently protected IEC-6 cells from !-irradiation-induced DNA damage, OTP at 
concentrations greater than 1 µM conferred significantly higher protection (Fig. 2.2A). 
Both OTP and LPA applied at 10 !M significantly protected IEC-6 cells from either 
topoisomerase inhibitor camptothecin- or the proinflammatory cytokine TNF-$-induced 
DNA damage as compared to control (p<0.001), and at this concentration OTP showed 
stronger antiapoptotic activity than did LPA (p<0.05, Fig. 2.2B). OTP and LPA 
significantly inhibited caspase 3 and caspase 9 activity induced with  !-irradiation; again, 
the OTP-induced inhibition was significantly higher than that of LPA (p<0.05, Fig. 
2.2C). Furthermore, analysis of caspase 3 activation by Western blotting demonstrated 
that both OTP and LPA significantly inhibited the conversion of the 32-kDa procaspase 
into its active form, and OTP showed significantly higher inhibition compared to LPA 
(Fig. 2.2D. p<0.05). Lastly, a brief 15-min OTP treatment inhibited the TNF-$-induced 
activation of caspase 8 (Fig. 2.2E) that provides further support for its effect in reducing 
apoptosis elicited via the extrinsic pathway. These results together indicate that OTP 
mimics the antiapoptotic action of LPA in IEC-6 cells that express LPA1 and LPA2 
receptors (Deng, 2002). 
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Figure 2.2.  OTP is more effective in reducing apoptosis than LPA in IEC-6 cells. 
IEC-6 cells were washed twice and starved in serum-free DMEM overnight. (Panel A) 
OTP (circles) or LPA (squares), ranging from 0 to 30 µM, was applied 15 min before 
25Gy !-irradiation. DNA fragmentation was evaluated 18 h postirradiation as described 
under Methods. (Panel B) IEC-6 cells were treated with 10 µM OTP or LPA before 
exposure to 20 µM camptothecin or 20 ng/ml TNF-" plus 10 µg/ml cycloheximide. DNA 
fragmentation was evaluated 6 h later. Con designates non-treated control cells, Veh 
denotes cells treated with vehicle (10!M BSA). (Panel C) Vehicle, 10 µM OTP or LPA, 
was applied to IEC-6 cells 15 min before 25 Gy -irradiation. Caspase 3 and caspase 9 
activities were measured 18 h postirradiation by ELISA. (Panel D) Western blot analysis 
of caspase 3 activation in LPA- and OTP-treated (10 !M each) IEC-6 cells 15 min prior 
to 25Gy  !-irradiation. A total of 20 !g cytosolic protein was loaded for each lane. (Panel 
E) A 15-min OTP or LPA pretreatment inhibits 20 ng/ml TNF-" plus 10 µg/ml 
cycloheximide-induced caspase 8 activity. * p < 0.01 compared to the appropriate control 
group. Data shown are means ± SD of at least three experiments. 
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2.3.6 The Antiapoptotic Activity of OTP Requires PTX-sensitive G Protein, Mitogen 
Activated Protein Kinase and PI3-Kinase/AKT Signaling 
  
We have previously shown that in IEC-6 cells the antiapoptotic action of LPA 
requires PTX-sensitive G protein, MEK, and PI3-kinase signaling (Deng, 2003). We 
found that OTP, just like LPA, activated ERK1/2 and p38 MAPK and AKT 
phosphorylation (Fig. 2.3A-C). We did not detect JNK phosphorylation under identical 
conditions (data not shown). To evaluate whether these same signaling mechanisms are 
required for OTP- elicited antiapoptotic activity, we examined these pathways by using 
pharmacological inhibitors and exposing these cells to OTP or LPA with or without 25 
Gy !-irradiation. In nonirradiated cells, just like LPA, OTP treatment for 5 min induced a 
significant increase in ERK1/2, p38, and AKT phosphorylation (Fig. 2.3). Blocking of 
ERK1/2 and AKT activation upstream by the MEK inhibitor PD98059 and PI3K 
inhibitor LY294002 completely abolished both OTP- and LPA-elicited activation, as well 
as protection (Fig. 2.3A, C, and D), indicating that the antiapoptotic activity of OTP 
required the activation of the ERK1/2 and AKT pathways. Pretreatment of IEC-6 cells 
with PTX completely abolished LPA-elicited ERK1/2 and AKT activation (Fig. 2.3A and 
C). In agreement with the requirement for a PTX-sensitive G protein in the antiapoptotic 
mechanism, PTX cancelled LPA-elicited protection from !-irradiation-induced DNA 
damage. In contrast, although PTX abolished OTP-induced AKT phosphorylation, it only 
partially attenuated ERK1/2 activation, indicating that OTP-stimulated ERK1/2 
activation was mediated through not only PTX-sensitive G proteins. In support of this 
result, PTX pretreatment only partially reduced OTP-initiated protection, which remained 
statistically significant following treatment with this toxin (p < 0.05, Fig. 2.3D). These 
results indicate some similarities, as well as differences, between the signaling pathways 
used by OTP and LPA. Because LPA1 and LPA2 are the two main EDG family receptors 
expressed in IEC-6 cells (Deng, 2003) and also in the mouse intestine (Deng, 2002; Li, 
2005a), we next compared the role of the individual LPA receptors in the LPA- and OTP-
elicited antiapoptotic response. 
 
 
2.3.7 OTP Selectively Protects LPA2 Transfectants from TNF-!-induced Apoptosis 
 
RH7777 cells do not endogenously express the EDG-family LPA receptor but 
express low amounts of LPA5 transcripts (Lee, 2006). When LPA or OTP was applied to 
wild type RH7777 cells exposed to TNF-" plus cycloheximide to induce apoptosis, 
neither compound applied at 10 !M attenuated DNA fragmentation (Fig. 2.4A). In 
contrast, in RH7777 cells individually transfected with LPA1, LPA2, or LPA3, DNA 
fragemtnation was significantly reduced by LPA pretreatment (Fig. 2.4A). OTP applied 
at 10 !M showed no significant antiapoptotic activity in LPA1 or LPA3 stable 
transfectants but evoked highly significant protection in the LPA2 transfectants, 
surpassing the effect of that of 10 !M LPA (Fig. 2.3A, p < 0.001). It is important to note 
that OTP and LPA both activate Ca2+ transients in LPA1, LPA2, or LPA3 transfectants 
(Fig. 2.1C) but not in wild type RH7777 cells. Thus, the antiapoptotic effect of OTP is 
not simply linked to activation of receptor-elicited Ca2+ mobilization but to the activation
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Figure 2.3.  Activation of prosurvival signaling pathways by LPA and OTP in IEC-6 
cells. IEC-6 cells were pretreated with pertussis toxin (PTX, 50 ng/ml) overnight, 
PD98059 (20 µM) for 1 h, or LY294002 (10 µM) for 30 min, followed by the addition of 
10 µM OTP or LPA. Activation of ERK1/2 (Panel A), P38 MAPK (Panel B), and 
PKB/AKT (Panel C) was evaluated by Western blot 5 min after treatment with 10 !M 
OTP or LPA. A total of 20 !g lysate protein was loaded for each lane. (Panel D) IEC-6 
cells were exposed to 25 Gy !-irradiation 15 min after OTP or LPA treatment (10 !M). 
DNA fragmentation was evaluated 18 h postirradiation. *p < 0.05 compared to irradiation 
alone. **p < 0.01 compared to irradiation alone. Data shown are means ± SD of at least 
three experiments. 
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Figure 2.4.  OTP selectively protects LPA2 transfectants against TNF" /CHX-
induced apoptosis. RH7777 cells were transfected with empty pCDNA3.1 vector or 
LPA1, LPA2, or LPA3 and pre-incubated with 10 µM OTP or LPA for 15 min, followed 
by TNF-" (20 ng/ml) plus CHX (10 µg/ml) exposure to induce apoptosis (Panel A). Note 
that whereas LPA reduced TNF"/CHX-induced DNA fragmentation in all three 
transfectants, OTP was effective only in LPA2 cells. Both ligands elicited Ca
2+ transients 
in these same cell lines (cf. Fig. 2.1C). LPA1 and LPA2 transfectants (Panel B) were 
pretreated with pertussis toxin overnight (PTX, 50 ng/ml), the MEK inhibitor PD98059 
(20 µM) for 1 h, or the PI3K inhibitor LY294002 (10 µM) for 30 min, followed by the 
addition of 10 µM OTP or LPA for 15 min and challenged with TNF-" (20 ng/ml) plus 
CHX (10 µg/ml). DNA fragmentation was evaluated 6 h after TNF"//CHX  addition. The 
reduction in DNA fragmentation was partially sensitive to PTX in LPA2 cells and was 
abolished in LPA1 cells. *p < 0.05, **p < 0.001 compared with TNF"//CHX alone. Data 
shown are means ± SD of three experiments. 
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of more complex signals originating from a specific receptor subtype, which is LPA2. 
The protective effect of LPA in LPA1 and LPA2 transfected RH7777 cells was abolished 
by PTX and was cancelled by pharmacological blockade of MEK/ERK1/2 and 
PI3K/AKT activation, which mirrors our findings in IEC-6 cells (compare Fig. 2.4B and 
2.3D). Just as in IEC-6 cells, the protective effect of OTP in RH7777 LPA2 transfectants 
was only partially PTX-sensitive and was completely abolished only by blocking ERK1/2 
and PI3K/AKT pathways (Fig. 2.4B). These results identify LPA2 in this model system as 
the main target of OTP and pinpoint a mechanism that involves MEK/ERK1/2 and 
PI3K/AKT activation mediated through multiple PTX-insensitive and -sensitive G 
proteins. LPA2 is known to be coupled to Gq and it mediates ERK1/2 activation in part 
(Ishii, 2000), a finding consistent with the partial inhibitory effect of PTX on the 
apoptotic effect found in IEC6, as well as in LPA2 transfected RH7777 cells. However, 
this finding does not explain why OTP, unlike LPA, failed to attenuate apoptosis in 
LPA1- or LPA3-transfected RH7777 cells even though it activated these receptor subtypes 
indicated by the Ca2+-responses (Fig. 2.1C). 
 
 
2.3.8 OTP Attenuates Radiation-induced Apoptosis in the Intestine  
 
We have previously demonstrated that LPA given orally prevents apoptosis 
induced by #-irradiation in the stem cell region of the intestinal crypt (Deng, 2002). Here, 
we sought to test whether OTP exerted a similar effect and compared its antiapoptotic 
efficacy with that of LPA by quantifying apoptotic bodies in the jejunal epithelium 4 h 
after 15 Gy #-irradiation (~LD100/10). In agreement with our previous report (Deng, 2002) 
using ICR animals was less than 0.5 per crypt-villus unit (Fig. 2.5A). In vehicle-treated 
(100 !L of 200 !M BSA in PBS) wild type C57BL/6 mice, the number of apoptotic 
bodies per crypt-villus unit increased 6-fold 4 h following #-irradiation. Oral pretreatment 
with LPA (2 mg/kg into the stomach 2 h before irradiation) significantly reduced the 
number of apoptotic bodies per crypt-villus unit (p<0.01, Fig. 2.5A). Oral OTP 
pretreatment (same timing and dose as LPA) reduced the number of apoptotic bodies by 
50%, which was significantly higher than that elicited by LPA (p<0.05, Fig. 2.5A). 
Analysis of the distribution of the apoptotic bodies along the crypt-villus unit showed that 
!-irradiation resulted in a high frequency of apoptotic cells over the stem cell zone of the 
crypt, four to seven cell positions from the base (Fig. 2.5B). Both LPA and OTP 
significantly reduced the number of apoptotic cells over the stem cell zone in the 
irradiated animals.  
 
Our data using the RH7777 heterologous over-expression model indicated that 
OTP elicited its antiapoptotic action through the LPA2 receptor subtype (Fig. 2.4). To 
evaluate which LPA receptor mediates the protective effect of OTP in vivo, we 
performed the same treatments in LPA1 and LPA2 knockout mice. We detected no 
differences in the basal count of apoptotic bodies between wild type C57BL/6 mice and 
LPA1 or LPA2 KO mice on this same genetic background. Surprisingly, #-irradiation 
induced a significantly higher rate of apoptosis at the base of the crypt that includes a 
small number of stem cells in LPA2 knockouts compared to that in wild type mice, 
whereas there was no difference between wild type and LPA1 mice (Fig. 2.5A). LPA and 
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Figure 2.5.  OTP inhibits apoptosis in small intestinal epithelium of mice following 
!-irradiation. Wild type C57BL/6 (black bars) and LPA1 (grey bars) or LPA2 KO mice 
(open bars) were given vehicle orally (100 !l 200 !M BSA control), LPA (2 mg/kg) or 
OTP (2mg/kg) 2 h before subjecting them to 15 Gy whole body !-irradiation. Animals 
were sacrificed 4 h after irradiation to evaluate apoptosis in the small intestine by H&E 
staining. (Panel A) The mean number of apoptotic cells per crypt-villus unit. Both LPA 
and OTP caused a statistically significant decrease in the number of apoptotic bodies 
compared to the vehicle-treated animal group (p < 0.01). Furthermore, OTP was 
significantly more effective than LPA (*p < 0.05). The number of apoptotic bodies was 
significantly higher in the LPA2 KO mice compared to wild type or LPA1 mice (*p < 
0.01). (Panel B) Correlation between apoptotic cell index (percentage of apoptotic cells at 
a given cell position) and their positions along the crypt-villus axis. Cells 1-2 are Paneth 
cells in the graph. n = 6 animals in each group, and a minimum of 100 crypt-villus units 
were scored in each group. (Panel C) Reverse-transcription PCR analysis of LPA GPCRs 
in jejunum isolated from wild-type, LPA1
-/-, and LPA2
-/- mice. 
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OTP had the same protective effect in wild type and LPA1 mice. In contrast, LPA and 
OTP failed to attenuate #-irradiation-induced apoptosis in LPA2 KO mice. In wild type 
animals the biggest radiation-induced increase in apoptotic bodies was found in the stem 
cell region of the crypt (Fig. 2.5B). LPA and OTP caused the biggest decrease in the 
number of apoptotic cells in this region of the crypt suggesting that the cellular targets of 
LPA and OTP are the stem cells. RT-PCR analysis of the LPA receptors showed that all 
but LPA4 transcripts were expressed in the tissue (Fig. 2.5C). The LPA1 and LPA2 KO 
animals showed no compensatory change in the expression of the other LPA receptors. 
Thus the in vivo data are consistent with our findings that LPA2 is required for the 
antiapoptotic effect of OTP. Nonetheless, these data differ from the findings in the case 
of LPA and point to the essential role of LPA2 in mediating the in vivo antiapoptotic 
effect of LPA. Furthermore, the increased rate of apoptosis in LPA2 KO mice suggests 
that this receptor may play a physiological role in the radiation sensitivity of the small 
intestine. These results also point to the fundamentally different role of the two LPA 
receptor subtypes in radiation sensitivity and apoptotic protection. 
 
Next, we sought to obtain direct evidence that LPA and OTP treatments activate 
the same signal transduction mechanisms we have identified. First, we examined whether 
LPA and OTP attenuate the activation of the main executioner, caspase 3, as we have 
seen in IEC-6 cells (Fig. 2.1C). Jejunum and ileum sections were immunostained with an 
antibody specific for the activated form of caspase 3, and the number of positive cells 
was counted in a minimum of 100 crypt-villus units in slides prepared from groups of 
four animals. In the nonirradiated vehicle-treated group, we could not detect caspase 3 
positive cells, possibly due to the low amount of antigen present in cells naturally 
undergoing apoptosis combined with their low incidence in the healthy small intestine. In 
contrast, in the vehicle-treated irradiated group, caspase 3 positive cells were readily 
detected. Both LPA and OTP treatments significantly reduced the number of activated 
caspase 3 positive cells by ~60% (Fig. 2.6A, p<0.05). The inhibition of caspase 3 
activation by LPA and OTP was also confirmed in intestinal epithelial lysates by 
measuring enzymatic activity (Fig. 2.6B). These experiments revealed that, in control 
nonirradiated animals, a low level of caspase 3 substrate cleaving activity is present, 
which increased 4-fold after 15 Gy !–irradiation. LPA and OTP reduced caspase 3 
activity significantly, although the inhibitory effect of OTP was greater. 
 
Our previous and present studies using IEC-6 and other types of cells (Deng, 2003 
& 2004) have established the requirement of ERK1/2 and AKT activation in the 
antiapoptotic response to LPA and OTP. We next determined whether these pathways 
were activated in intestinal cell homogenates prepared from animals that have been 
treated with the two ligands by oral gavage. As shown in Fig. 2.6 C-D, both agents 
activated ERK1/2 and AKT phosphorylation as early as 30 min after administration in 
nonirradiated animals. However, the effect of OTP was considerably longer lasting in the 
tissue compared to the effect of LPA, which was absent in the samples collected 60 min 
after administration.  
 
Studies using IEC-6 cells showed that LPA upregulated the expression of the 
antiapoptotic Bcl-2 mRNA and had no effect on Bcl-XL, BAD, and Bak mRNA
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Figure 2.6.  OTP and LPA reduces caspase 3 activation and activates prosurvival 
pathways in vivo. C57BL/6 mice were pretreated with 2 mg/kg LPA or OTP for 2 h and 
subjected to 15 Gy radiation exposures. Mice were sacrificed 4 h after radiation. (Panel 
A) Quantification of active caspase 3 immunoreactive cells. Paraffin-embedded jejunum 
sections from animals treated with radiation and pretreated with either LPA or OTP were 
stained with a rabbit polyclonal active caspase 3 antibody and fluorescein-labeled 
secondary antibody using indirect immunofluorescence as described under Methods, and 
the sections were counterstained with DAPI. Active caspase 3 immunoreactive cells were 
counted in a minimum of 100 crypt-villus units in groups of four animals in the groups. 
Both agents significantly reduced the number of activated caspase 3 positive cells (p< 
0.05) when compared with vehicle-treated controls. (Panel B) Caspase 3 activity was 
determined in epithelial cell lysates prepared from the same animals whose jejunum 
segments were used for activated caspase 3 immunostaining in panel A. LPA and OTP 
both significantly reduced caspase 3 activity in the tissue lysates, a finding in agreement 
with the reduced number of active caspase 3 cells. (Panels C-D) Jejunum tissue from 
mice orally treated with vehicle, 2 mg/kg LPA, or OTP for the indicated times were 
homogenized and lysates analyzed using Western blotting with anti-phospho-ERK1/2 (C) 
or anti-phospho-AKT antibodies (D) and appropriate antibodies to the nonphosphorylated 
forms of the kinases to monitor equal loading. Note that the activation of both kinases 
was more robust and longer lasting to OTP compared to LPA. 
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from LPA- and OTP-treated mice 4 h after irradiation (6h after treatment), we could not 
detect a significant change in Bcl-XL or Bcl-2 expression (data not shown). However, 
immunostaining with a Bcl-XL specific antibody revealed marked increases in LPA and 
OTP treated animals (Fig. 2.7) compared to jejunum and ileum (not shown) from the 
vehicle-treated animals. OTP treatment caused the most intense immunostaining (Fig. 
2.7C), although LPA also elicited a substantial increase in the immunoreactivity (Fig. 
2.7B). When we tested the level of in Bcl-XL or Bcl-2 protein in OTP-treated 
camptothecin-challenged IEC-6 cells a transient increase in Bcl-XL but not in Bcl-2 was 
detected (Fig. 2.7D). These results taken together establish strong similarities, as well as 
some differences, between the prosurvival signals elicited by these two agents in cultured 
cells and the small intestinal tissue in vivo. 
 
 
2.3.9 OTP and LPA Enhance Intestinal Crypt Survival after Radiation Injury 
 
!-Irradiation induces apoptosis in crypt cells, which in turn reduces the 
regenerative or clonogenic potential leading to the disruption of the barrier and absorptive 
function in the injured gut. We examined the effect of LPA and OTP on crypt survival in 
irradiated mice using H&E staining and BrdU incorporation to monitor regenerating S-
phase enterocytes. Irradiation with a dose of 15 Gy caused a 90% reduction in the number 
of crypts in jejunum in wild type mice within 4 days (Figs. 2.8 and 2.9). Oral LPA or 
OTP pretreatment enhanced intestinal crypt survival in a dose-dependent manner (Fig. 
2.8A). OTP treatment of mice with doses above 0.2 mg/kg significantly enhanced crypt 
survival, while LPA treatment required a minimum dose of 1.0 mg/kg to cause a 
significant protection in crypt survival (p<0.05, Fig. 2.8A). OTP at doses above 1 mg/kg 
maintained a significantly greater number of crypts than did LPA (p<0.05, Fig. 2.8A). 
Followed by 15 Gy #-irradiation, OTP orally applied at 2 mg/kg increased the number of 
surviving crypts in the jejunum from 10 crypts to an average of 27 crypts per 
circumference (Fig. 2.8A). To further validate LPA2 as the target of the antiapototic 
action of LPA and OTP, we also examined crypt survival in LPA2 KO mice treated the 
same way as their wild type counterparts described above. In contrast to irradiated wild 
type mice, LPA1 and particularly LPA2 KO mice showed lower crypt survival. However, 
in LPA1 KO mice LPA and OTP both elicited significantly increased crypt survival, 
which was not significantly different from that seen in wild type mice treated the same 
manner. LPA2 KO mice revealed significantly higher radiation sensitivity. Whereas in 
wild type mice exposed to a 15 Gy dose the mean crypt survival per circumference was 
10, in LPA2 KO mice it was as little as 1 crypt/circumference (Fig. 2.8B). Neither LPA 
nor OTP applied at 2 mg/kg, the highest dose tested, showed any effect in enhancing 
intestinal crypt survival in the LPA2 KO mice. This observation extends the increased 
rate of apoptosis, the lack of treatment-induced reduction in apoptotic cells observed in 
the LPA2 KO mice, ending strong support to the hypothesis that LPA2 is the molecular 
target of radioprotective effect of LPA and OTP. 
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Figure 2.7.  Immunohistochemical localization of antiapoptotic Bcl-XL protein in 
vehicle (200 !M BSA), LPA- and OTP-pretreated, irradiated small intestinal 
sections of C57BL/6 mice. Sections of vehicle-treated mice (A) showed less Bcl-XL 
expression compared to sections obtained from mice treated with 2mg/kg LPA (B) or 
OTP (C). Calibration bar is 200 !m. The patterns shown represent sections obtained from 
all mice in the corresponding group of four mice per treatment. Panel C. OTP increases 
the cytoplasmic level of Bcl-XL but not Bcl-2 in camptothecin-treated IEC-6 cells. After 
overnight serum starvation, IEC-6 cells were pretreated with 10 !M OTP or vehicle for 
1h prior to challenge with 20 µM camptothecin (Cam). A 20 !g cytoplasmic protein was 
loaded for each lane and blotted with anti- Bcl-XL or Bcl-2 antibodies as described under 
Materials and Methods. Note that OTP increased the amount of Bcl-XL but not of Bcl-2 
that peaked at 2 h after camptothecin and decreased to control level by 4 h. 
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Figure 2.8.  Clonogenic assays reveals increased intestinal crypt survival in OTP- 
and LPA-treated mice following irradiation. (Panel A) Wild type C57BL/6 mice were 
given vehicle (BSA 200 !M), LPA, or OTP (0 to 2 mg/kg) orally 2 h before being 
subjected to 15 Gy whole body !-irradiation. (Panel B) Wild type C57BL/6 (black bars), 
LPA1 KO (grey bars) or LPA2 KO mice (open bars) were orally given vehicle, LPA, or 
OTP, 2 mg/kg, 2 h before 15 Gy !-irradiation, and the animals were sacrificed 4 days 
after irradiation. Crypt survival was evaluated by H&E staining combined with BrdU 
immunostaining. n=6 in each group. Data are expressed as means ± SD of surviving 
crypts per cross section. The level of significance based on Student t test was *p < 0.05, 
or **p < 0.01, between the designated groups, and was #p < 0.01 compared to irradiation 
alone and between the mean crypt survival in wild type and LPA1 and LPA2 KO mice.  
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Figure 2.9.  Representative H&E stained gut cross-sections from treated LPA1 and 
LPA2 KO mice sacrificed 4 days after irradiation. Nonirradiated control (A), 
irradiated vehicle-treated (B), LPA-treated (C, 2 mg/kg), and OTP-treated WT (D, 2 
mg/kg), vehicle treated LPA1 and LPA2 KO (panels E & G) and OTP (2 mg/kg) treated 
LPA1 KO (F) and LPA2 KO (H) mice. Calibration bar is ~500 !M. 
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2.3.10 OTP Reduces Radiation-induced Death 
 
Although orally applied OTP did not get absorbed into the systemic circulation in 
an effective concentration but reduced radiation-induced cell death in the small intestine 
we reasoned that if administered systemically, it might exert a protective effect on 
survival. To test this hypothesis we turned to an intraperitoneal route of administration 
and monitored 30 d survival as the primary endpoint following a 9 Gy dose of !-
irradiation, which in our system approximately equals a LD100/30 (Fig. 2.10). The group of 
mice that received a 0.5 mg/kg dose 30 min prior to irradiation, we observed a 50 per 
cent survival to the end of the experiment whereas, all animals in the vehicle treated 
group died. These results expand the potential usefulness of OTP from the topical 
protection of the small intestine following oral route of administration to a 
radiomitigating agent effectively reducing death caused by the hematopoietic syndrome.  
 
 
2.4     DISCUSSION 
 
The objective of the present study was to evaluate the effect of OTP, a rationally 
designed metabolically stabilized LPA mimic, on radiation-induced apoptosis in vitro and 
in vivo. Our data indicate that OTP is a highly effective antiapoptotic agent that engages 
prosurvival pathways similar to those elicited by LPA through the LPA2 receptor 
subtype. OTP shares a pharmacological profile similar to that of LPA in that it activated 
the three EDG family LPA receptors expressed heterologously in RH7777 cells. The rank 
order of OTP’s EC50 values was LPA2 (90 nM) < LPA3 < LPA1 based on Ca
2+ transients  
 
 
 
 
 
Figure 2.10.  OTP administered intraperitoneally 30 minutes prior to irradiation 
with a 9 Gy dose (LD100/30) increased 30-day survival. 
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elicited in this heterologous expression system. These values render OTP a considerably 
weaker ligand of the three LPA receptors compared to LPA 18:1. OTP when compared to 
LPA in three different apoptosis models, which included radiation- and camptothecin-
elicited DNA damage-induced and TNF-"/CHX-elicited extrinsic mechanisms, always 
surpassed the protective effect of LPA. In agreement with the cellular models of 
apoptosis, OTP was more effective in reducing the number of apoptotic bodies, caspase 3 
positive cells, and caspase 3 activity in C57BL/6 mice exposed to an LD100/15 dose of !-
irradiation.  
 
What may account for the higher efficacy of OTP relative to LPA in spite of its 
weaker pharmacological potency? Although we cannot pinpoint a single reason for the 
increased efficacy of OTP, there are major differences in its metabolic resistance and 
bioavailability compared to LPA. First, we found that OTP was not cleaved by pancreatic 
lipase, the major lipase in the intestine. Second, it is not degraded by lipid phosphate 
phosphatase 1, which is the other major mechanism for the inactivation of LPA 
(Brindley, 2002). Third, due to the lack of a glycerol backbone, unlike LPA, OTP cannot 
be acylated by lysophosphatidate transacetylases. Fourth, likely due to its polar character, 
OTP does not transverse the cell membrane readily, and we could not detect radioactively 
labeled OTP in the blood of experimental animals following application via oral gavage. 
These differences in its metabolism and bioavailability relative to LPA might represent 
some of the causes for its higher efficacy in the apoptosis assays. The observation that 
OTP elicited ERK1/2 and AKT phosphorylation with longer duration in the mouse 
intestinal tissue certainly supports this hypothesis. At the same time, the lack of 
absorption of [3H]-OTP into the systemic circulation within a 3-h period, which appears 
to be the limit for the duration of its protective time window (data not shown), indicates 
that it exerts its effect topically from within the intestinal lumen without appearing in a 
pharmacologically and biologically effective concentration in the bloodstream. 
Radioactively labeled LPA has been shown to be taken up rapidly (within minutes) into 
cells where it is rapidly dephosphorylated and reacylated (van der Bend,1992); 
nevertheless, ~15% remains intact in the cytoplasm up to 30 min after extracellular 
application (Tokumura, 1992). These differences in bioavailability could, at least in part, 
explain the differences in the in vivo efficacy of OTP compared to LPA. 
 
Another important difference was that the LPA2 receptor subtype is sufficient and 
necessary for the antiapoptotic effect of OTP. In the receptor reconstitution experiments 
carried out in RH7777 cells stably transfected with the individual receptor subtypes, 
although OTP activated Ca2+ transients through each receptor subtype, only cells 
expressing LPA2 were protected against apoptosis. In agreement with the role of LPA2 in 
this model system, experiments conducted in LPA2 KO mice confirmed that this receptor 
was absolutely necessary for the attenuation of apoptosis and increased crypt survival 
elicited by OTP. A third line of evidence, namely the increased radiation sensitivity of 
LPA2 KO gut tissue compared to wild type animals, suggests that this receptor subtype is 
uniquely involved in mediating prosurvival signals. Only if we assign the prosurvival 
function to LPA2 can it explain the lack of protective effect in response to LPA 
administration observed in the LPA2 KO mice, which continue to express LPA1 and 
LPA3 (Contos, 2002). RT-PCR analysis has identified only the LPA1 and LPA2 receptor 
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subtypes in the mouse intestine, as well as in IEC-6 cells used in the present study (Li, 
2005; Yun, 2005). The partial sensitivity of the OTP-elicited antiapoptotic response to 
PTX is consistent with the Gq-coupling of LPA2 (Ishii, 2000). However, LPA also 
showed antiapoptotic protection in RH7777 cells expressing either LPA1 or LPA3 in the 
TNF-"/CHX induced apoptosis model. The RH7777 cells show extreme resistance to 
radiation (Deng & Tigyi unpublished) that precluded studying the radioprotective effect 
exerted by these receptors in this model. We do not understand the reasons for this 
difference and can only speculate that either the higher than physiological level of 
receptor over-expression or the differences in the protective signaling mechanism 
between the TNF-"/CHX and the DNA damage-induced mechanisms could be part of the 
reason. We also found that caspase 8 activity was attenuated by OTP indicating that LPA 
receptor signaling affects the upstream part of the extrinsic apoptotic pathway. Whether 
this inhibition of caspase 8 activation is unique to LPA2 or also elicited by other receptor 
subtypes should be evaluated in future experiments. While this unanswered question does 
not detract from the importance of LPA2 in the radioprotective mechanisms activated by 
LPA or OTP and the natural radiation sensitivity of the gut tissue, further experiments 
will have to be designed to resolve this apparent contradiction. LPA2 is distinct from the 
other two subtypes in that its C-terminus has been shown to interact with PDZ and LIM 
domain-containing proteins (Oh, 2004; Xu, 2004; Lai, 2005; Li, 2005a; Yamada, 2005). 
LPA2 can signal through specific protein-protein interactions in a non-G-protein-coupled 
manner and access triple LIM domain-containing proteins including TRIP6, zyxin, LPP, 
and Siva-1 (Xu, 2004; Lai, 2005; Takizawa, 2006). G protein-linked activation of c-src 
by LPA2 phosphorylates TRIP6, which in turn augments LPA-induced ERK activation 
(Lai, 2005) and could lead to increased BAD phosphorylation and inhibition of 
procaspase 9 (Fang, 1999). The potential interaction of LPA2 with Siva-1 offers an 
exciting possibility, because DNA damage-induced activation of Siva-1 scavenges the 
antiapoptotic Bcl-XL (Xue, 2002; Chu, 2004; Gudi, 2006). LPA2 could capture Siva-1 
and enable Bcl-XL to attenuate apoptosis triggered by DNA damage. Our findings 
concerning the increased level of Bcl-XL in IEC-6 cells and OTP-treated gut favor this 
hypothesis. The PDZ domain-mediated interactions including the PDZ-binding protein 
NHERF2 provide yet another link with antiapoptotic signaling, because stable 
knockdown of NHERF2 in CaCo-2 cells has been found to attenuate LPA2-induced 
ERK1/2, AKT, and PLC$ activation (Oh, 2004; Yun, 2005). These potential signaling 
interactions between LPA2 and LIM or PDZ domain proteins await further investigation. 
 
Orally administered OTP may offer other uses that reach beyond the protection of 
the GI system. Orally applied OTP is unlikely to be useful for reducing apoptosis in the 
hematopoietic system, because it does not get absorbed to a biologically effective 
concentration in the systemic circulation. However, experiments done with 
intraperitoneal application of OTP in irradiated C57BL/6 mice caused a significant 
reduction in lethality mitigating the lethality of the LD100/30 dose to equal that of a LD50/30 
outcome. Thus, OTP’s applicability for systemic treatment of radiation illness should be 
the focus of the next experiments. 
 
In summary, the present study identifies OTP as an orally active antiapoptotic 
agent that targets LPA2 and distinct prosurvival signals coupled to this receptor.  The 
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simple chemical nature of OTP, combined with its metabolic resistance, limited systemic 
bioavailability, and its apparently low acute oral toxicity (> 10 mg/kg) make this 
compound a reasonable candidate for treating radiation injury of the gut and warrant 
further investigation for its potential therapeutic uses.  
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CHAPTER 3. INTERACTION OF LPA2 WITH LIM AND PDZ DOMAIN 
PROTEINS MEDIATES ITS PROTECTION AGAINST APOPTOSIS 
 
 
3.1     INTRODUCTION 
 
LPA is a phospholipid growth factor mediating diverse cellular responses via its 
cognate LPA receptors that belong to the G-protein coupled receptors (GPCRs). By 
coupling to Gi, Gq, G12/13 and Gs, LPA receptors mediate a vast array of biological and 
pathological responses including cell growth, survival, differentiation, migration and 
cancer invasion in response to LPA stimulation (Mills & Moolenaar, 2003 Review). So 
far seven LPA receptors have been identified. LPA1, LPA2, and LPA3 belong to the EDG 
family and share more than 50% homology (Anliker & Chun, 2004 review). LPA4 
(GPR23) and LPA5 (GPR92) belong to a purinergic P2Y receptor subfamily (Noguchi, 
2003; Kotarsky, 2006). Unlike LPA1-3, LPA4 and LPA5 mediate an increase in cAMP 
production (Noguchi, 2003; Kotarsky 2006; Lee, 2006). GPR87 (potential LPA6) and 
P2Y5 (potential LPA7), also belonging to the P2Y family, have recently been determined 
to be LPA receptors (Tabata, 2007; Shimomura, 2008). P2Y5 is found to be essential for 
maintenance of human scalp hair growth (Pasternack, 2008; Shimomura, 2008).  
 
Substantial evidence has shown that LPA is a potent survival and antiapoptotic 
factor capable of arresting the apoptotic pathway in apoptotically condemned cells. LPA 
protects various cell lines from apoptosis induced by different apoptotic stimuli that 
include serum-deprived apoptosis in fibroblasts (Fang, 2000), macrophages (Koh, 1998), 
T cells (Goetzl, 2000), Schwann cells (Weiner, 1999; Li, 2003), renal proximal tubular 
cells (Levine, 1997), intestinal epithelial cells (Deng, 2002; 2007); chemotherapeutic 
agents-induced apoptosis in BJAB and I-83 B cell lines, primary chronic lymphocytic 
leukemia (CLL) cell lines (Hu, 2005), prostate cancer cells (Raj, 2004), intestinal 
epithelial cells (Deng, 2002; 2007), colon cancer cell lines (Rusovici, 2007), ovarian 
cancer cell lines (Frankel, 1996; Meng, 2005); death receptor-induced apoptosis (Kang, 
2004; E, 2007), and radiation-induced apoptosis in epithelium (Deng, 2002; 2007). The 
protection against apoptosis by LPA is mainly mediated by LPA1 and LPA2. ERK and/or 
Akt/PKB signaling pathways have been identified to mediate the LPA anti-apoptotic 
effects in most of these cell lines (Radeff-Huang, 2002 review). Previously we found 
OTP, an LPA mimic, protects epithelial cells from radiation-induced apoptosis both in 
vivo and in vitro (E, 2007). We also determined that only LPA2 reconstitution of RH7777 
cells devoid of EDG family LPA receptors but not reconstitution with LPA1 or LPA3 was 
capable of rescuing these cells from TNF"-induced apoptosis. In support of the essential 
role of LPA2, neither LPA nor OTP protected the intestinal mucosa of LPA2 knockout 
mice from radiation-induced apoptosis, whereas both ligands were active in LPA1 
receptor knockouts. LPA2 is over-expressed in several cancer cell lines such as ovarian, 
colon and thyroid cancer cell lines (Zheng, 2000; Schulte, 2001; Fang, 2004; Shida, 
2004; Rusovici, 2007), where it could contribute to the therapeutic resistance of these 
cancers by increasing their apoptotic resistance to radiation and chemotherapy. However, 
the molecular mechanisms of rescuing apoptotically challenged cells distinctive to LPA2 
remain unknown. 
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More and more evidence shows that GPCR can also relay signal through 
mechanisms distinct from the classical G protein-dependent signaling paradigm (Brady & 
Limbird 2002 review; Hall & Lefkowitz, 2002 review; Rajagopal, 2005 review; 
McGarrigle, 2007 review; Sun, 2007 review, Lefkowitz, 2007 review). These novel 
mechanisms involve signal transduction through macromolecular complex formation of 
GPCR by protein-protein interaction with adaptor or scaffold proteins. Examples of these 
adaptor proteins are $-arrestins (Lefkowitz, 2006) and PDZ domain containing proteins 
(Hung & Sheng, 2002 review). AT1 receptor having mutations in the second intracellular 
DRY motif lacks G protein coupling mediates activation of Src-Ras-ERK pathway (Seta, 
2002). The conserved YIPP motif in the AT1 cayboxyl terminus interacts with SHP2, 
which in turn mediates Jak/STAT pathway and EGF receptor (Marrero, 1998; Seta, 
2003). In addition, Sadoshima’s group has provided the most compelling evidence using 
transgenic mice that G protein-independent signal transdution via AT1R results in 
ventricular hypertrophy and bradycardia with a diminished apoptosis and a unique 
signaling profile (Zhai, 2005). Huang’s group has demonstrated dose-dependent switch of 
G protein-coupled to G protein-independent signaling by $2- ARs (Sun, 2007) 
 
LPA1, LPA2, and LPA3 share high, over 80%, sequence homology in their 
transmembrane domains, whereas the carboxyl termini show a mere 11% homology. 
Intriguingly only the CT of LPA2 receptor, among the three EDG subtypes, can form 
protein-protein complexes with PDZ and LIM domain proteins (Lin, 2008 review). The 
identification of an increasing list of binding proteins unique to LPA2-CT warrants 
further study on the role of protein-protein interaction in mediating the function of LPA2 
(Oh, 2004; Wang, 2004; Xu, 2004; Yamada, 2005; Lin, 2007; Zhang, 2007). 
 
The PDZ domain is a modular protein-interaction domain that consists of around 
90 amino acids. It is named after the three founding PDZ-containing proteins: the 
postsynaptic protein PSD-95/SAP90, the Drosophila septate junction protein Disc-large, 
and the tight junction protein ZO-1. So far, at least four PDZ-containing proteins have 
been found to interact with LPA2: Na
+/ H+ exchange regulatory factor 2 (NHERF2) (Oh, 
2004; Yun, 2005), PDZ-RhoGEF (Yamada, 2005), leukemia-associated RhoGEF (Wang, 
2004), and membrane associated guanylate kinase-like protein with an inverted domain 
structure-3 (MAGI-3) (Zhang, 2007). The best-studied PDZ domain protein interacting 
with LPA2-CT is NHERF2, which contains two tandem PDZ domains capable of 
bridging two proteins that contain PDZ motifs. The second PDZ domain of NHERF2 
interacts specifically with LPA2 via its CT motif (D-S-T-L), but not with LPA1 or LPA3 
(Oh, 2004; Li, 2005a). Knockdown of NHERF2 in Caco-2 cells attenuates LPA2-
mediated ERK1/2 and Akt activation (Oh, 2004; Yun, 2005). Moreover, the LPA2 
receptor forms a macromolecular complex with Cystic Fibrosis Transduction Regulator 
(CFTR) and NHERF2 via the second PDZ domain (Li, 2005a). LPA attenuates cholera 
toxin-induced secretory diarrhea via formation of the protein-protein interaction complex 
between LPA2 and CFTR Cl
- channel (Li, 2005a). It is not clear whether association with 
these PDZ proteins mediates the anti-apoptotic function of LPA2. 
 
Recently, the LIM domain proteins Thryoid Hormone Receptor Interacting 
Protein 6 (TRIP6) and the proapoptotic transcriptional coregulator Siva-1 have been 
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found to interact with LPA2 by yeast two-hybrid system (Xu, 2004; Lin, 2007). The LIM 
domain is named by the acronym of three homeodomain proteins: Lin-11, Isl-1 and Mec-
3. It usually consists of approximately 55 amino acids with 8 highly conserved residues, 
mostly cysteine and histidine located at defined intervals, which constitute two sequential 
zinc-finger structures linked by a two-peptide linker (Fig 1.3) (Bach, 2000 review; 
Kadrmas & Beckerle, 2004 review; Zheng & Zhao, 2007 review). TRIP6 belongs to the 
LIM domain protein subfamily of Zyxin, which consists of Zyxin, LPP (lipoma preferred 
partner) and Ajuba (Beckerle, 1997 review; Yi & Beckerle, 1998). The Zyxin family is 
associated with actin cytoskeleton reorganization Siva-1, though functionally unrelated to 
Zyxin family, shares structural similarity with TRIP6 in that it contains two carboxyl 
cysteine-rich zinc finger motifs and these cysteines are also present in the human and rat 
homologues (Prasad, 1997; Lin, 2007). 
 
TRIP6 contains an N-terminal proline-rich domain, three LIM domains and a 
PDZ protein-binding motif at its CT (Yi, 1998; Xu, 2004). All three LIM domains are 
involved in interaction with LPA2. This association promotes LPA-dependent recruitment 
of TRIP6 to the focal adhesion where it interacts with focal adhesion molecules: focal 
adhesion kinase, p130CAS, paxillin and c-Src. Interestingly, c-Src can phosphorylate 
TRIP6 at Tyr-55 and this phosphorylation enhances the LPA-induced ERK1/2 activation. 
Knockdown of TRIP6 drastically attenuates LPA-induced ERK1/2 activation in c-Src 
expressing cells (Lai, 2005). Recently the same group has found that PTPL1/FAP-1 
dephosphorylates TRIP6 at Tyr-55, which provides a negative regulation of the LPA-
induced morphological change and cell migration (Lai, 2007). Furthermore, LPA 
activates Src (Luttrell, 1996) and inhibition of Src by the specific inhibitor PP2 abolishes 
its protective effect (Deng & Tigyi - unpublished). TRIP6 also potentiates receptor-
interacting protein 2 (RIP2)-mediated NF-'B and ERK activation (Li, 2005b). These 
observations suggest that TRIP6 could be involved in mediating the anti-apoptotic effect 
of LPA2 by ERK activation, which is a required signal for the protective effect of LPA 
(Deng, 2003, E, 2007). 
 
Siva-1 is a pro-apoptotic molecule initially discovered by using the cytoplasmic 
tail of CD27 as bait in a yeast two-hybrid system (Prasad, 1997). Siva-1 is not related to 
either death domain containing proteins like FADD or TNFR associated factors (TRAFs) 
domain proteins. Also, Siva-1 does not contain any Bcl-2 Homology (BH) domains. So it 
is not related to Bcl-2 family members. Over-expression of Siva-1 in various cell lines 
induced apoptosis (Prasad, 1997). Siva-1 expression is regulated by p53 and E2F1 
(Fortin, 2004) and is up regulated during DNA damage responses (Qin, 2002; Daoud, 
2003; Fortin, 2004: Lin, 2007). Interestingly, Siva-1 also binds to Bcl-XL and inhibits 
Bcl-XL mediated protection against UV radiation-induced apoptosis (Xue, 2002). A 
putative amphipathic helical region of Siva-1 is found to be sufficient to bind Bcl-XL and 
sensitize cells to UV radiation-induced apoptosis (Chu, 2004). The underlying 
mechanism of apoptosis promotion of Siva-1 involves cytochrome C release and 
activation of caspases 9 and 3. In T lymphocytes, overexpression of Siva proteins induces 
apoptosis via a caspase-dependent mitochondrial pathway (Py, 2004). Most interestingly, 
Siva-1 is found to interact LPA2-CT (Lin, 2007). The promoting effect of Siva-1in DNA 
damage-induced apoptosis is inhibited by LPA pretreatment (Lin, 2007). LPA2 forms a 
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macromolecular complex with Siva-1 and this complex becomes polyubiquitinated in 
response to LPA stimulation of cells and in turn the complex is degraded in the 
proteasome. Knockdown of LPA2 expression increases Siva-1 protein levels and 
augments adriamycin-induced caspase-3 activation and apoptosis (Lin, 2007). Perhaps 
not just a coincidence that LPA up regulates Bcl-XL levels at the posttranscriptional level 
in culture intestinal epithelial cells and also in the gut epithelium of mice treated with 
OTP (E, 2007). This coincidence provides the foundation for our hypothesis that 
interaction of Siva-1 with LPA2 is involved in the antiapoptotic rescue mechanism. 
However, it is not clear how LPA2 interacts with Siva-1 and attenuates its proapoptotic 
function. 
 
In this work we have mapped out the motif in LPA2-CT that mediates interaction 
with TRIP6 and Siva-1 and examined LPA2 downstream signaling involved in apoptosis 
protection via disruption of its interaction with LIM and/or PDZ domain proteins. 
 
 
3.2     MATERIALS AND METHODS 
 
 
3.2.1 Materials 
 
LPA (18:1) was purchased from Avanti Polar Lipids (Alabaster, AL). Fura-2/AM, 
Alexa fluor 488 donkey anti-mouse IgG conjugate, TRIzol, DNase I and ThermoScript 
RT-PCR System for First-Strand cDNA Synthesis were obtained from Invitrogen 
(Carlsbad, CA). Bovine serum albumin (BSA; fraction V, fatty acid-free), mouse 
monoclonal and rabbit polyclonal anti-Flag M2 antibody and affinity gel, normal donkey 
serum, and 2-bromopalmitate were from Sigma. Rabbit anti-phospho-anti-ERK1, rabbit 
anti-phospho-AKT, rabbit anti-AKT IgG were from Cell Signaling Biotechnology 
(Worcester, MA). Anti-Mouse and anti-rabbit IgG HRP conjugate were from Promega 
(Madison, WI). Plasmid extraction kit was from Qiagen (Valencia, CA). Restriction 
enzymes were from New England Biolab (Beverly, MA). RT2 Real-Time SYBR 
Green/ROX was from SuperArray (Frederick, MD). Re-Blot plus strong solution (10X) 
was from Chemicon (Temecula, CA). Adriamycin was from Teva Pharmaceuticals 
(Pennsylvania). 
 
  
3.2.2 Plasmid Construction and Site-directed Mutagenesis 
 
The wild type (WT) N-terminal FLAG epitope-tagged human (h)LPA2 receptor 
construct subcloned into the pcDNA3.1 expression plasmid was provided by Dr. Junken 
Aoki (University of Tokyo, Tokyo, Japan). Truncation mutations were generated using T7 
primer: 5’-TAA TAC GAC TCA CTA TAG GG-3’ and the corresponding reverse primer 
designed to contain the PDZ binding motif DSTL and Xbal restriction sites (Table 3.1.). 
The PCR product was digested with EcoR I and Xba l, subcloned into pcDNA3.1. 
Alanine mutants were generated overlapping extension PCR with primers containing site-
specific mutations (Table 3.2.) and T7 (see above) and BGH reverse primer (5’-
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Table 3.1.  Primer sequences for hLPA2 truncation mutants. 
 
Truncation    
mutation 
Primer sequence 
!302+ 
DSTL 
5' - GCT CTA GAC TAC AGA GTT GAA TCC ATC TCA GCA TCT CGG CAA G - 3' 
 
 
!309+ 
DSTL 
5' - GCT CTA GAC TAC AGA GTT GAA TCA AGG CGG CGG AAG GTG CG - 3' 
 
 
!316+ 
DSTL 
5' - GCT CTA GAC TAC AGA GTT GAA TCG CGG AGG CAC GCG CAG CA – 3 
 
' 
!327+ 
DSTL 
5' - GCT CTA GAC TAC AGA GTT GAA TCG GAT GTA TAG TGG ACA GAC TC- 3' 
 
 
!338+ 
DSTL 
5' - GCT CTA GAC TAC AGA GTT GAA TCC ATG ATG CGA GTG CTG GCA CC-3’ 
 
 
!347 5' - GCT CTA GAC TAC ATC AGT GGG TGG CCG TTC TC - 3' 
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Table 3.2.  Primer sequences for hLPA2 alanine point mutants. 
 
Mutation Codon Mutated codon Primer sequence 
C297A TGC GCT F:5’GTGTACTCTGCTCGAGATGCT3’ 
R:5’AGCATCTCGAGCAGAGTACAC3’ 
 
R298A CGA GCA F:5’GCTGCTGTGTACTCTTGCGCAGATGCTGAGATGC3’ 
R:5’GCATCTCAGCATCTGCGCAAGAGTACACAGCAGC3’ 
 
D299A GAT GCT F:5’TCTTGCCGAGCTGCTGAGATG3’ 
R:5’CATCTCAGCAGCTCGGCAAGA3’  
 
E301A GAG GCT F:5’CTCTTGCCGAGATGCTGCTATGCGCCGCACC3’ 
R:5’GGTGCGGCGCATAGCAGCATCTCGGCAAGAG 
 
R303A CGC GCT F:5’CTCTTGCCGAGATGCTGAGATGGCTCGCACCTTCC3’ 
R:5’GGAAGGTGCGAGCCATCTCAGCATCTCGGCAAGAG3’ 
 
R304A CGC GCT F:5’TGAGATGCGCGCTACCTTCCGC3’ 
R:5’GCGGAAGGTAGCGCGCATCTCA3’ 
 
T305A ACC GCT F:5’GAGATGCGCCGCGCTTTCCGCCGCCTTC3’ 
R:5’GAAGGCGGCGGAAAGCGCGGCGCATCTC3’ 
 
F306A TTC GCT F:5’CCGCACCGCTCGCCGCCTTCT3’ 
R:5’AGAAGGCGGCGAGCGGTGCGG3’ 
 
R307A CGC GCT F:5’GATGCGCCGCACCTTCGCTCGCCTTCTCTGCTG3’ 
R:5’CAGCAGAGAAGGCGAGCGAAGGTGCGGCGCATC3’ 
 
R308A CGC GCT F:5’ACCTTCCGCGCTCTTCTCTGC3’ 
R:5’GCAGAGAAGAGCGCGGAAGGT3’ 
 
L309A CTT GCT F:5’TTCCGCCGCGCTCTCTGCTGC3’ 
R:5’GCAGCAGAGAGCGCGGCGGAA3’ 
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Table 3.2. (Continued). 
 
  
Mutation Codon Mutated codon Primer sequence 
C312A TGC GCT F:5’CTTCTCTGCGCTGCGTGCCTC3’ 
R:5’GAGGCACGCAGCGCAGAGAAG3’ 
 
R316A CGC GCT F:5’CTGCGCGTGCCTCGCTCAGTCCACCCGCGAG3’ 
R:5’CTCGCGGGTGGACTGAGCGAGGCACGCGCAG3’ 
 
C314A/L351A TGC/CTT GCT/GCT F: 5’TCTGCTGCGCGGCTCTCCGCCAGT3’ 
R: 5’ACTGGCGGAGAGCCGCGCAGCAGA3’ 
 
C314G/L351A TGC/CTT GGT/GCT F:5’TCTGCTGCGCGGGTCTCCGCCAGT3’ 
R:5’ACTGGCGGAGACCCGCGCAGCAGA3’ 
 
C311A/C314A TGC/TGC GCT/GCT F:5’CGCCTTCTCGCTTGCGCGTGC3’ 
R:5’GCACGCGCAAGCGAGAAGGCG3’ 
 
C311A/C314A/L351A TGC/TGC/CTT GCT/GCT/GCT F:5’CGCCTTCTCGCTTGCGCGTGC3’ 
R:5’GCACGCGCAAGCGAGAAGGCG3’ 
 
C311A/C312A/C314A TGC/TGC/TGC GCT/GCT/GCT F:5’CGCCTTCTCGCTGCTGCGGCTCTCCGCCAG3’ 
R:5’CTGGCGGAGAGCCGCAGCGAGAAGGCG3’ 
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TAGAAGGCACAGTCGAGG). hLPA2 WT and the generated mutants were digested 
with EcoR I and Not I and subcloned into pcDNA3.1/Zeocin (+)
 
vector (Invitrogen). 
Mutated DNA was transformed into TOP10-competent
 
cells (Invitrogen), and clones 
were verified by complete sequencing
 
of the inserts. The L351A mutant was a kind gift 
from Dr. A.P. Naren (Li, 2005a). 
 
 
3.2.3 Cell Culture and Transfection 
 
EDG-family LPA receptor null RH7777 (RH) cells (ATCC, Manassas, VA) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (Hyclone, Logan, UT) and antibiotics (Invitrogen). Cells were 
transfected using Effectene according to manufacturer’s protocol (Qiagen). 
  
Primary Mouse Embryonic Fibroblasts (MEFs) were isolated from E13.5 LPA1/2 
Double knockout (DKO) embryos (Yue, 2004) and maintained in DMEM supplemented 
with 10% fetal bovine serum and antibiotics. Primary MEFs were immortalized by 
transfection with SV40 large T antigen or by selecting spontaneously immortalized cells. 
Genotype of LPA1/2 DKO MEFs was confirmed as described previously (Contos, 2002).  
 
 
3.2.4 Construction of LPA2 -Lentiviral Vectors and Production of Lentivirus 
  
pcDNA3.1-hLPA2 WT and mutants were digested with XhoI and filled in with 
DNA polymerase Klenow, then re-digested with NheI and the cDNA fragment was 
purified. The lentiviral vector pcFUW-puro was excised with BamHI and filled in with 
Klenow, then re-excised with Xba I. The LPA2 wild type and mutant cDNA fragments 
were purified and subcloned into Xba I and blunted BamH I sites of pcFUW-puro. The 
recombinant lentivirus was produced in 293FT cells (Invitrogen) by co-transfection of the 
lentiviral transfer vector with the ViraPower Packaging Mix (Invitrogen) containing 
plasmids, pLP/VSVG, pLP1/gag-pol, and pLP2-Rev. The supernatant was collected 60 h 
after transfection and centrifuged 15 min at 3000 x g at 4 °C to remove cell debris, then 
the supernatant was passed through 0.45 µm filter and collected for ultra-centrifugation at 
54000 x g for 3 h at 4 °C. The virus pellet was dissolved in PBS and stored at -80 °C. The 
viral particles were titrated in 293 FT cells using p24 ELISA assay (PerkinElmer, Boston, 
MA). Stable MEFs expressing GFP, empty vector, WT LPA2 and the different LPA2 
mutants were derived by transduction with lentiviruses and selected with 1.5 µg/ml 
puromycin. 
 
 
3.2.5 Ligand-induced Ca
2+
 Activation Assay 
 
RH7777 cells plated in 6-well plates were transiently transfected with either 2 !g 
of WT LPA2 or its mutants and cultured for 24 h and replated onto 0.1 mg/ml poly-L-
lysine-coated 96-well microplates (Corning Incorporated Life Sciences, Acton, MA) at 3 
x 10
4
 cells/well. Lentivirus-transduced LPA1 and LPA2 double knockout MEFs stably 
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expressing WT LPA2 and its mutants, LPA1 KO MEFs (express endogenous level of 
LPA2) were plated onto poly-L-lysine-coated 96-well microplates at a density of 4 x 10
4
 
cells/well and cultured overnight. RH cells after 5 h serum starvation or MEFs with no 
serum starvation were loaded with Fura-2/AM in Krebs buffer (120 mM NaCl, 5 mM 
KCl, 0.62 mM MgSO4, 1.8 mM CaCl2, 10 mM HEPES, pH 7.4, 6 mM glucose) 
containing 2% (v/v) pluronic acid at 37 °C for 30 min. The cells were rinsed with Krebs 
buffer and monitored in a FLEXStation (Molecular Devices, Sunnyvale, CA) at 
excitation wavelengths of 340/380 nm and an emission wavelength of 510 nm for 70 sec 
after the addition of different concentration of LPA 18:1 or 10 µM ATP (positive 
control).  
 
 
3.2.6 Western Blot 
    
ERK1/2 and Akt were measured in total cellular protein lysates by using a 
previously described procedure (E, 2007). Briefly, lentivirus-transduced stable mock, WT 
LPA2 MEFs and those expressing the LPA2 mutants were plated at 80% confluence and 
cultured overnight. On the second day, cells were serum starved for 2.5 h and treated with 
1 µM LPA for indicated times. Cells were lysed in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 
25% glycerol plus phosphatase and protease inhibitor cocktail (Sigma). The lysates were 
sonicated twice for 5 s, cleared by centrifugation at 1.6 x 10
4
 g for 15 min at 4 °C, and the 
supernatants were collected. Protein concentrations were determined using the BCA 
reagent kit (Pierce Biotechnology, Inc., Rockford, IL). For ERK1/2 15 !g, Akt 80 !g of 
cell lysate was fractionated by SDS-PAGE and transferred to PVDF membranes, blocked 
with 5% nonfat milk, and incubated with various primary antibodies. Blots were reacted 
with the appropriate HRP-conjugated secondary antibodies and developed using the 
SuperSignal chemiluminescence reagent (Pierce Biotechnology, Inc). Images were 
visualized with Fotodyne image analysis system (Fotodyne Inc., Hartland, WI). 
 
 
3.2.7 Reverse-transcription PCR 
 
Total RNA was extracted from spontaneously immortalized LPA1 and LPA2 
double knockout MEFs stably expressing WT LPA2, LPA2-C311A/C314A, LPA2-L351A 
or LPA2-C311A/C314A/L351A or GFP using TRIzol reagent. Two µg total RNA was 
digested by DNase I. 400 ng of the digest was subjected to reverse transcription PCR 
using the Superscript III kit to amplify LPA2. Primers sets were: forward, 5’-
CACTCCTGGCACTGCCTCTGTG-3’, reverse, 5’-TACGGCGCATCTCAGCGTCTC 
G-3’. !-actin, forward, 5’-GACAACGGCTCCGGCATGTG-3’, reverse, 5’-
TTGAGACCTTCAACACCCCAGCA -3’. A total of 31 amplification cycles were 
performed and the products were separated in 2% agarose gels, stained with ethidium 
bromide for visualization. 
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3.2.8 Quantitative Real Time-PCR 
 
Total RNA was prepared from spontaneously immortalized LPA1 and LPA2 
double knockout MEFs stably expressing WT LPA2, LPA2-C311A/C314A, LPA2-L351A 
or LPA2-C311A/C314A/L351A or GFP using TRIzol. One !g of total RNA was digested 
with DNase I and used for the subsequent synthesis of cDNA using the First Strand 
Synthesis kit as recommended by the manufacturer. The following primer pairs were 
used: LPA1: (forward) GTCTTCTGGGCCATTTTCAA and (reverse) 
TCATAGTCCTCTGGCGAACA; LPA2: (forward) GGGCCAGTGCTACTACAACG 
and (reverse) ACCAGCAGATTGGTCAGCA; LPA3: (forward) 
GAAGCTAATGAAGACGGTGATGA and (reverse) AGCAGGAACCACCTTTTCAC; 
LPA4: (forward) TCTGGATCCTAGTCCTCAGTGG and (reverse) 
CCAGACACGTTTGGAGAAGC; LPA5: (forward) CGCCATCTTCCAGATGAAC and 
(reverse) TAGCGGTCCACGTTGATG; LPA6( GPR87): (forward) 
AAATCCAGCAGGCAATTCAT and (reverse) CCCTGATGCTCTGGTTATGTT ; 
LPA7 (P2ry5): (forward) TCTGGCAATTGTCTACCCATT and (reverse) 
TCAAAGCAGGCTTCTGAGG; !-actin: (forward) TTCTACAATGAGCTGCGTGTG 
and (reverse) GGGGTGTTGAAGGTCTCAAA. The primer sets were designed with 
melting temperatures in the 59–61 °C range and the amplicon size was 50–200 bp. 
Amplification was performed for 40 cycles at 94 ºC/15 sec and 60 ºC /60 sec. 
Quantitative values of the threshold cycle value (Ct), were determined using an ABI-
Prism (manufacturer, city state) Q-PCR Instrument. The transcript number of 
(human/mouse/rat) !-actin was quantified to serve as internal RNA control, and each 
sample was normalized on the basis of its !-actin content. The relative expression level 
of each gene was then normalized to the calibrator. Final results, expressed as fold 
difference in gene expression relative to !-actin and gene of interest, termed N, were 
calculated as: N = 2
(Ct gene - Ct calibrator)
 (http://dorakmt.tripod.com/genetics/realtime.html), 
where Ct values of the gene and calibrator were determined by subtracting the average Ct 
value of a target gene from the corresponding Ct value of the !-actin gene. 
 
 
3.2.9 Flow Cytometry Analysis 
  
RH cells plated in 6-well plates were transfected with 0.4 !g of DNA using 
Effectene.
 
After 24 h incubation, the cells were serum starved for 6 h and trypsinized with 
HyQtase (Hyclone), washed twice with ice-cold FACS buffer consisting of phosphate-
buffered
 
saline (PBS) supplemented with 3% (w/v) BSA, incubated in blocking buffer 
(PBS, 5% BSA, 5% normal donkey
 
serum) for 30 min, washed with FACS
 
buffer three 
times and incubated with monoclonal antibody
 
in blocking buffer (1:100 dilution) for 1 h. 
The anti-FLAG-stained cells were rinsed in FACS
 
buffer three times, and incubated in 
the dark at 4 °C with
 
AlexaFluor 488-conjugated donkey anti-mouse IgG at 1:1600 
dilution
 
for 30 min. The cells were rinsed three times with FACS buffer
 
and analyzed 
using an LSR II flowcytometer (Becton Dickinson,
 
San Jose, CA). 
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3.2.10 Cellular Co-immunoprecipitation and GST Pull-down 
 
Cellularco-immunoprecipitation of Siva-1 or TRIP6 with the LPA receptors and 
the truncation and alanine point mutant swas performed as described previously (Xu, 
2004). Briefly, HEK 293T cells transiently expressing MYC-TRIP6 with LPA2, or its 
mutants were starved in 0.1% fatty acid-free BSA containing DMEM for 8h to overnight 
followed by the stimulation with 2 !M LPA for 10 min. The LPA2 was 
immunoprecipitated with the anti-FLAG M2 mouse monoclonal antibody-conjugated 
agarose beads (Sigma), resolved by SDS-PAGE, and the immunoblot was probed with an 
anti-MYC rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) to 
detect the co immunoprecipitated MYC-TRIP6. The blots were stripped and reprobed 
with an anti-FLAG rabbit polyclonal antibody (Sigma) to detect the FLAG-LPA2 
receptor. To detect the cellular interaction of LPA2 with Siva-1, MYC-Siva-1 was co-
expressed with LPA2 in HEK 293T cells. After starvation overnight, cells were harvested 
and the co-immunoprecipitation was performed as described above. MYC-Siva-1 co-
immunoprecipiated with FLAG-LPA2 was detected with an anti-MYC rabbit polyclonal 
antibody. 
 
To detect direct binding of Siva-1 or TRIP6 with the carboxyl-terminal tail of the 
LPA2 receptor, GST, GST-Siva-1, GST-TRIP6, GST-LPA2-CT or its alanine mutants 
were expressed in (BL21)(DE3)(LysS) E. coli and purified by immobilizing the proteins 
on glutathione-Sepharose 4B beads (Amersham Biosciences, Piscataway, NJ). GST-Siva-
1 and GST- TRIP6 was further digested with PreScission Protease (Amersham 
Bioscience) to cleave off the GST tag. 1 µg of TRIP6 or 0.1 µg of Siva-1 protein was 
incubated with 1 µg of GST, GST-LPA2-CT or its mutants in the binding buffer (20 mM 
Tris, pH7.4, 1 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40) for 3 h at 4 
o
C. Siva-1 or 
TRIP6 protein pulled down by GST-LPA2-CT or alanine mutants was detected with an 
anti-Siva-1 polyclonal antibody (affinity purified anti-Siva-1 polyclonal antibody raised 
against human Siva-1 peptide aa30-44, Lin, 2007) and TRIP6 specific anitibody 
(Transduction Laboratory, San Jose, CA), respectively. 
 
 
3.2.11 Immunocytochemistry 
  
To examine co-localization of Siva-1 with the LPA2 receptor, GFP-Siva-1 was co-
expressed with the FLAG-LPA2 or its mutants in SV40 T-antigen-transformed LPA1 and 
LPA2 double knockout MEFs. Cells were starved overnight in 0.1% BSA-containing 
medium.  After fixation, permeabilization and blocking, cells were incubated with an 
anti-FLAG M2 monoclonal antibody followed by a Texas Red X-conjugated anti-mouse 
secondary antibody (Invitrogen) to detect FLAG-LPA2 constructs. The nuclei were 
counter stained with Hoechst 33258 (Sigma). The images of GFP and GFP-Siva-1 were 
captured by fluorescence microscopy using a Zeiss Axioplan 2 microscope. 
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3.2.12 Palmitoylation  
 
HEK 293T cells were transfected with the plasmids indicated. Cells were labeled 
with [
3
H] palmitic acid at 37ºC for 2 h. The FLAG-LPA2 receptor was 
immunoprecipitated with an anti-FLAG M2 monoclonal antibody-conjugated agarose 
beads, resolved by SDS-PAGE and detected by autoradiography and by immunoblotting 
with an anti-FLAG antibody, respectively.  
 
 
3.2.13 Acyl-Biotinyl Exchange Method 
 
GFP-Siva-1 or GFP-TRIP6 was co-expressed with the FLAG-LPA2 receptor in 
HEK 293T cells. After treatment with 100 µM 2-BP in 0.1% BSA-containing DMEM for 
4 h, cells were stimulated with LPA for 10 min, and the FLAG-LPA2 receptor was 
immunoprecipitated with the anti-FLAG antibody-conjugated agarose beads. Half of the 
precipitates were resolved by SDS-PAGE and the immunoblot was probed with an anti-
GFP polyclonal antibody to detect GFP-Siva-1 and GFP-TRIP6, respectively. The rest of 
the samples were subjected to acyl-biotinyl exchange (ABE) chemistry to determine the 
levels of palmitoylated LPA2 receptor (Roth, 2006a). Briefly, the precipitated LPA2 
receptor was pre-treated with N-ethylmaleimide (NEM) followed by the acyl-biotinyl 
exchange with hydroxylamine and biotin-HPDP. The biotinylated FLAG-LPA2 receptor 
was eluted from the beads using excess FLAG peptides for competition, and then 
precipitated with avidin beads. After SDS-PAGE, the immunoblot was probed with an 
anti-FLAG antibody to detect the palmitoylated FLAG-LPA2 receptor.  
 
 
3.2.14 Adriamycin-induced Siva-1 Expression, Procaspase-3 Cleavage and Apoptosis 
 
The spontaneously immortalized LPA1 and LPA2 double knockout MEFs stably 
expressing WT LPA2, LPA2-C311A/C314A, LPA2-L351A or LPA2-
C311A/C314A/L351A were incubated with 10 !M LPA in 0.1% BSA-containing 
DMEM for 2 h followed by the addition of 1.5 !M adriamycin for 14 h and harvested. 
Halves of the samples were subjected to FITC-annexin V staining (BD Biosciences), and 
the apoptosis was determined by flow cytometry. The other halves of the samples were 
subjected to immunoblotting. The expression of procaspase-3 and Siva-1 in the total 
lysates was detected with a rabbit polyclonal antibody specific to caspase-3 (Santa Cruz 
Biotechnology) and Siva-1, respectively.   
 
 
3.2.15 DNA Fragmentation Assay 
   
DNA fragmentation was measured by ELISA following the procedure provided 
with the Cell Death Detection kit from Roche, Inc. (Indianapolis, IN) as described 
previously (Deng 2002 & 2003) and was expressed as absorbance units at 405 nm per 
microgram protein per minute. Briefly, the spontaneously immortalized LPA1and LPA2 
double knockout MEFs stably expressing WT LPA2, or its mutants were plated the night 
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before the assay, at a density of 0.11x 10
6
 per well on 24-well plates coated with 0.1 
mg/ml poly-L-lysine. On the second morning, cells were rinsed twice with DMEM 
containing 0.5% FBS and treated with 3 µM adriamycin for 6 h. 2 µM LPA was added 1h 
after adriamycin treatment. The duplicate plate was used for protein assay with the BCA 
kit. 
 
 
3.2.16 Statistical Analysis of Data 
   
Data are expressed as means ± SD/SEM.  Each experiment was repeated at least 
three times. Student t test was used for comparing different groups. A p value of < .05 
was considered significant. 
 
 
3.3     RESULTS 
 
 
3.3.1 Spaced Cysteine Residues in LPA2-CT May Constitute Potential Zinc-finger 
Binding Structure to TRIP6/Siva-1 
 
Previously it has been shown that aa 296-351 of LPA2 is required for interaction 
with TRIP6 and Siva-1, but not LPA1 or LPA3 (Xu 2004; Lin, 2007). TRIP6 possesses 3 
LIM domains at its CT (aa 278-476) and all of them contribute to the binding of LPA2. 
While Siva-1 has 2 zinc finger motifs at its CT (aa114-138 and aa142-170), only the 
second (aa 142-170) interacts with LPA2. Comparison of amino acid sequences between 
the second zinc finger domain of Siva-1 and TRIP6-LIM3 reveals conserved cysteine 
residues at defined intervals, which is the characteristic feature of LIM domains (Fig. 3.1 
& Fig. 1.4). LPA2 is distinctly different from the other receptor subtypes in its C- 
terminal tail (Fig. 3.1). Whereas the homology between LPA1, LPA2, and LPA3 in the 
transmembrane regions is 81%, in the C-terminal tail there are only 6 conserved amino 
acids in 55 (11%). Among the 21 residues in CTs of LPA1, LPA2 and LPA3 that were 
aligned with zinc finger structure of TRIP and Siva-1, there are three conserved, spaced  
 
 
 
 
 
Figure 3.1.  Amino acid sequence alignment of human Siva-1, TRIP6 and LPA 
receptor-CTs. 
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cysteine residues in LPA2 compared to one in LPA1 and LPA3 (Fig. 3.1). Since zinc-
finger mediates protein-protein interaction, we hypothesize that these cysteine residues 
may constitute the binding motif of LPA2 to TRIP and/or Siva-1. 
 
 
3.3.2 TRIP6 and Siva-1 Binding Motif Is Mapped to aa309-316 of LPA2-CT 
 
To map out the domain in the LPA2-CT that mediates interaction with the LIM 
proteins, we first generated deletion mutations that span the LPA2-CT region of aa 296-
351 but kept the PDZ motif intact in the mutants LPA2-"296, LPA2-"302+DSTL, LPA2-
"309+DSTL, LPA2-"316+DSTL, LPA2-"327+DSTL, or truncated it in the LPA2-
"338+DSTL, LPA2-"347, LPA2-"348 constructs, or mutated the critical leucine residue 
in the LPA2-L351A construct (Fig. 3.2). DSTL, the last four amino acids of the LPA2, is 
the PDZ binding motif and required for the interaction of LPA2 with NHERF2. The 
interaction is reduced by LPA2-L351A point mutant and completely abolished by LPA2-
"STL (Oh, 2004; Li, 2005a). These constructs together with GFP-TRIP6 were 
reconstituted into HEK 293T cells, which express a barely detectable level of endogenous 
TRIP6, and exposed to LPA stimulation for 10 min. The co-immunoprecipitation results 
of these mutants with TRIP6 showed that truncation mutant of LPA2-"309+DSTL and 
those of more N-terminal (LPA2-"296 and LPA2-"302+DSTL) could not pull down 
TRIP6. In contrast, LPA2-"316+DSTL and mutants extending beyong residue 316 
retained binding (Fig. 3.3). This indicates that a motif between amino acids 309-316 is 
required for the interaction of TRIP6 with LPA2.  
 
Previously it has been shown that upon LPA stimulation Siva-1 colocalizes with 
LPA2 in NIH3T3 fibroblasts (Lin, 2007). To examine association with Siva-1, GFP-Siva-
1 and LPA2 mutants were cotransfected into SV40 T-antigen transformed LPA1/2 double 
knockout (DKO) MEFs. As shown in Fig. 3.4, Siva-1 (green) was localized to nucleus,  
 
 
 
 
 
Figure 3.2.  Schematic illustration of the LPA2-CT deletion constructs. 
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Figure 3.3.  TRIP6 binding domain is localized between aa309-316 of LPA2-CT. 
GFP-TRIP6 and GST, GST-FLAG-LPA2 deletion mutant constructs were transfected into 
HEK293T cells. After starvation in 0.1% BSA-containing DMEM overnight, cells were 
incubated without or with 2 µM LPA for 10 min. The LPA receptors from the whole 
lysates were immunoprecipitated (IP) with anti-FLAG M2 monoclonal antibody-
conjugated agarose, resolved by SDS-PAGE, and transferred to nitrocellulose membrane 
for immunoblotting. The immunoblot (IB) was probed with an anti-GFP polyclonal 
antibody to detect coimmunoprecipitated GFP-TRIP6. The same blot was then stripped 
and reprobed with an anti-FLAG polyclonal antibody to detect immunoprecipitated 
LPA2. The bottom panel is an immunoblot showing the expression of GFP-TRIP6 in the 
whole cell lysates. Also note that mutation or deletion of the PDZ motif did not abolish 
but weakened the binding of TRIP6 compared to WT LPA2. 
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Figure 3.4.  Siva-1 binding domain is located between aa309-316 of LPA2-CT. DKO 
MEFs were transiently transfected with pEGFP-Siva-1 and an expression vector of 
FLAG-LPA2 or FLAG-LPA2 deletion mutant as indicated. After fixation, 
permeabilization and blocking, cells were incubated with an anti-FLAG M2 mouse 
monoclonal antibody followed by the Texas Red-X-conjugated anti-mouse secondary 
antibody to detect the wild type or mutant of FLAG-LPA2. The nuclei were stained with 
Hoechst 33258. GFP-Siva-1 was directly visualized by fluorescence microscopy. 
 
 65 
 
while LPA2 (red) is present at plasma membrane and the cytosol. LPA2 colocalization 
with Siva-1 (yellow) was detected in cells expressing WT LPA2 and LPA2-
"316+DSTL.The same findings were observed in cells expressing LPA2-"327+DSTL 
and LPA2-"338+DSTL (data not shown). However, no colocalization was observed in 
cells expressing LPA2-"296, LPA2-"302+DSTL, LPA2-"309+DSTL mutants. Thus, 
immunocytochemistry revealed the same requirement for Siva-1 binding to LPA2 as we 
found using coimmunoprecipitation with TRIP6, namely a motif between aa309-316 is 
required the interaction with Siva-1. 
 
Interestingly, two cysteine residues reside in the region between 309-316, which 
supports our hypothesis for the role of the zinc-finger like domain in this interaction. To 
map out the motif in this region, we carried out alanine scanning mutagenesis between 
residues 296-316. 
 
 
3.3.3 The C311xxC314 Motif of the LPA2 Receptor Is Required for Interaction with 
TRIP6 and Siva-1 
 
We started with alanine mutation of the conserved amino acids M302, L310, 
C311 and C314 because we hypothesized that some of these residues might play an 
important role in binding to LIM proteins. These alanine (or also glycine for C314) point 
mutants together with L351A were cotransfected into HEK 293T cells with myc-TRIP6. 
As shown in Fig. 3.5A, mutation of Cys311 and/or Cys 314 to alanine, but not other 
residues as indicated, abolished coimmunoprecipitation of TRIP6. It should be noted that 
on blots with long exposure, a very weak association of endogenous TRIP6 with C311A 
or C3114A could still be detected. In the case of Siva-1, C311A and C314A could still 
pulldown Siva-1, but not the C311AC314A double mutant (Fig. 3.5 B). Also 
colocalization of Siva-1 with these alanine mutants was examined. C311A and C314A 
abolished colocalization with Siva-1 (Fig. 3.6). Together, these findings suggest that 
C
311
xxC
314
 is required for interaction with TRIP6 or Siva-1. 
 
To exclude the requirement of other residues we performed alanine scanning of 
the domain aa296-316 in addition to those mutants shown above. With these alanine 
mutants, first we checked cellular (Fig. 3.7) and cell surface expression and ligand–
induced Ca
2+
 activation to make sure that mutation does not cause change of receptor 
function (Table 3.3). We found two residues D299 and E302, when mutated to alanine, 
lost their surface expression. All other mutants behaved as WT LPA2. 
Coimmunoprecipitation with these alanine mutants showed that all of them interacted 
with TRIP6, though with variation in degree (Fig. 3.8). Taken together, these results 
demonstrate that the C
311
xxC
314 
motif in the LPA2-CT is required for interaction with 
TRIP6 or Siva-1. 
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Figure 3.5.  The C311-x-x-C314 motif located at the proximal region of the 
carboxyl terminal tail of the LPA2 receptor regulates the cellular interaction with 
TRIP6 and Siva-1. (A) HEK 293T cells transiently expressing MYC-TRIP6 with WT 
LPA2, or its point mutants were starved in 0.1% BSA containing DMEM for overnight 
followed by stimulation with 2 !M LPA for 10 min. FLAG-LPA2, WT or mutant, was 
immunoprecipitated with the anti-FLAG M2 antibody-conjugated agarose beads, 
resolved by SDS-PAGE, and the immunoblot was probed with an anti-MYC rabbit 
polyclonal antibody to detect the coimmunoprecipitated MYC-TRIP6. The blots were 
stripped and reprobed with an anti-FLAG rabbit polyclonal antibody to detect the 
FLAG-LPA2 receptor. The bottom panel in each figure shows the expression of MYC-
TRIP6 in the total lysates. (B) To detect the cellular interaction of LPA2 with Siva-1, 
MYC-Siva-1 was coexpressed with WT LPA2 or its point mutants in HEK 293T cells. 
After starvation overnight, the cells were harvested and the co-immunoprecipitation 
was performed as described above. MYC-Siva-1 coimmunoprecipiated with LPA2 was 
detected by an anti-MYC rabbit polyclonal antibody. The cellular interaction of TRIP6 
and LPA2 is LPA-dependent. LPA stimulation for 5-10 min induces the association of 
TRIP6 with LPA2 on the membrane. At 15-20 min stimulation with LPA, TRIP6 is 
translocated to focal adhesions and associated with actin. In contrast, Siva1 binds to the 
LPA2 receptor in the absence of LPA. LPA stimulation for 30-60 min down-regulates 
the expression of both LPA2 and Siva-1. 
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Figure 3.6.  Mutation of both Cys311 and Cys314 to Alanine abolishes the 
colocalization of LPA2 with Siva-1. The SV40 T-antigen-transformed DKO MEFs 
were transiently transfected with pEGFP-Siva-1 with an expression vector of FLAG-
LPA2 or its mutants as indicated. After fixation, permeabilization and blocking, cells 
were incubated with an anti-FLAG antibody followed by Texas Red-X-conjugated 
anti-mouse secondary antibody to detect the wild type or mutant of FLAG-LPA2. 
GFP-Siva-1 was directly visualized by fluorescence microscopy. 
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Figure 3.7.  Cellular expression of LPA2-CT point mutants in RH cells. LPA2 point 
mutants as indicated were transfected into RH cells. The LPA receptor from the whole 
lysates was immunoprecipitated with anti-FLAG M2 monoclonal antibody-conjugated 
agarose, resolved by SDS-PAGE, and transferred to nitrocellulose membrane for 
immunoblotting. The immunoblot was probed with an anti-FLAG M2 monoclonal 
polyclonal antibody to detect immunoprecipitated LPA2. 
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Table 3.3.  Surface expression and ligand-induced Ca
2+
 mobilization of LPA2-CT 
mutants transiently expressed in RH cells. 
 
Mutation Codon Mutated 
 codon 
Surface 
Exp
#
 
(% cells) 
Ca
2+
 peak * 
C297A TGC GCT 25 0.63±0.05 
R298A CGA GCA 17.3 0.5±0.05 
D299A GAT GCT 2.7 0.11±0.04 
E301A GAG GCT 20 0.22±0.06 
M302A ATG GCA 2.5 0.13±0.05 
R303A CGC GCT 22.7 0.49±0.07 
R304A CGC GCT 21.5 0.39±0.06 
T305A ACC GCT 21.7 0.53±0.07 
F306A TTC GCT 13.8 0.48±0.06 
R307A CGC GCT 30.6 0.51±0.09 
R308A CGC GCT 33.2 0.35±0.04 
L309A CTT GCT 13.1 0.46±0.02 
L310A CTC GCT 20.2 0.69±0.03 
C311A TGC GCT 22.7 0.67±0.02 
C312A TGC GCT 32.7 0.81±0.11 
C314A TGC GCT 30.1 0.44±0.05 
L315A CTC GCT 32.2 0.46±0.06 
R316A CGC GCT 24.4 0.42±0.06 
C314AL351A TGC/CTT GCT/GCT 32.9 0.43±0.08 
C314GL351A TGC/CTT GGT/GCT 38.3 0.48±0.08 
C311AC314A TGC/TGC GCT/GCT 35.3 0.32±0.11 
311/314/351A TGC/TGC/CTT GCT/GCT/GCT 26.4 0.71±0.06 
Vector 3.1/Zeo(+)  2.1 0.08±0.05 
WT hLPA2  40 0.69±0.06 
 
#
 Expression. * In response to 1 µM LPA (18:1)
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Figure 3.8.  Alanine scanning of aa296-316 by coimmunoprecipitation with TRIP6. 
HEK 293T cells transiently expressing MYC-TRIP6 with WT LPA2, or its point mutants 
as indicated were starved in 0.1% BSA containing DMEM for 8 h followed by 
stimulation with 2 !M LPA for 10 min. The FLAG-tagged receptor constuct was 
immunoprecipitated with the anti-FLAG M2 antibody-conjugated agarose beads, 
resolved by SDS-PAGE, and blot was probed with an anti-MYC rabbit polyclonal 
antibody to detect the coimmunoprecipitated MYC-TRIP6. The blots were stripped and 
reprobed with an anti-FLAG rabbit polyclonal antibody to detect the FLAG-LPA2 
receptor. The bottom panel in each figure shows the expression of MYC-TRIP6 in the 
lysates. 
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3.3.4 LPA2 Receptor Directly Interacts with TRIP6 and Siva-1 via the C311xxC314 
Motif 
 
We next performed pull down experiments using purified recombinant proteins to 
examine the role of the C
311
xxC
314
 motif in the direct interaction with TRIP6 and Siva-1. 
The purified TRIP6 was pulled down by GST-LPA2-CT. However, none of C311A, 
C314A, C311A/C314A, C314A/L351A mutants and GST protein alone formed a 
complex (Fig. 3.9a). This indicates that the C
311
xxC
314
 motif is required for the direct 
interaction with TRIP6. In the case of Siva-1 (Fig. 3.9b), C311A or C314A mutant could 
still pull down some Siva-1, whereas C311A/C314A double mutant did not form a 
complex. This indicates Siva-1 binds more tightly to LPA2 than TRIP6 so that neither 
C311A nor C314A alone abolished the association. These finding indicate that the LPA2-
CT interacts directly with TRIP6 and Siva-1 via C 
311
xxC
314
 motif. 
 
 
3.3.5 Palmitoylation Does Not Affect the Interaction of LPA2 with TRIP6/Siva-1 
 
GPCR are known to be subject to post-translational lipid modifications mainly 
through palmitoylation that includes the attachment of palmitate to one or more of the 
cysteine residues through a thioester bonds. Palmitoylation of GPCR plays important 
roles in receptor binding, targeting, trafficking, signaling and protein interactions 
(Dunphy & Linder 1998; Qanbar & Bouvier, 2003 review; Escriba, 2007). Palmitoylation 
typically occurs on the cysteine residues proximal to the cytosolic end of the seventh 
transmembrane helix. The identification of the role of the C
311
xxC
314
 motif in LPA2-CT 
prompted us to investigate whether palmitoylation occurs on these cysteines and if yes, 
what role it plays in the interaction between LIM domain proteins and LPA2. WT LPA2 
and its Cys to Ala mutants, including residues Cys297, Cys311, Cys312 and Cys314 were 
transfected into HEK 293T cells. Cells were labled with [
3
H]-palmitic acid at 37 
o
C for 2 
h. The receptor was immunoprecipitated using anti-FLAG agarose as above, separated by 
SDS-PAGE and the immunoprecipitated protein was visualized by western blotting, 
whereas the incorporated [
3
H]-palmitate was detected by autoradiography. The result 
showed that C311A/C314A and C311A/C312A/C314A mutants have about 80% 
reduction of palmitoylation compared to WT (Fig 3.10A, B). However, even in the 
C311A/C312A/C314A mutant there is still detectable level of palmitoylation, indicating 
palmitoylation in cysteines outside of the LPA2-CT. Taken together, C311 and C314 
constitute sites of LPA2-CT palmitoylation. 
 
To examine the effect of palmitoylation in the interaction of LPA2 with TRIP6 
and Siva-1, 2-bromopalmitate (2-BP), a non-metabolizable palmitate analog that blocks 
palmitate incorporation into proteins, was used to block LPA2 palmitoylation (Webb, 
2000). As shown in Fig 3.11, 100 µM 2-BP treated for 30 min decreased the LPA2 
palmitoylation level to 20% of the control.  
  
Next we examined the effect of palmitoylation on the interaction of LPA2 with 
TRIP6 and Siva-1 by coimmunoprecipitation after treating the cells with 100 µM 2-BP 
for 4 h. the precipitated LPA2 receptor was pre-treated with N-ethylmaleimide (NEM) 
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Figure 3.9.  Mutation of LPA2-CT Cys311 or Cys314 to Alanine abolishes its direct 
binding to TRIP6; however, only when both are mutated binding to Siva-1 is 
completely eliminated.  GST-TRIP6 or GST-Siva-1 was purified from E. coli 
transformed with pGEX-6P3-TRIP6 or pGEX-6P3-Siva-1, and further digested with 
Precision Protease to cleave GST. One !g of TRIP6 or 0.1 !g of Siva-1 was incubated 
with one !g of GST or GST fusion protein of LPA2-CT  (aa 296-351), LPA2CT-C311A, 
LPA2CT-C314A or LPA2CT-C311A/C314A at 4 
o
C for 3 h. TRIP6 (A) or Siva-1 (B) 
pulled down by GST fusion proteins was resolved by SDS-PAGE and detected with an 
antibody specific to TRIP6 or Siva-1, respectively. The first lane shows the 10% input of 
TRIP6 or Siva-1 used in these experiments.  
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Figure 3.10.  Mutation of LPA2-CT cysteine residues inhibits receptor 
palmitoylation. (A) HEK 293T cells were transfected with the plasmids as indicated. 
Cells were labeled with [
3
H] palmitic acid at 37 
o
C for 2 h. The FLAG-LPA2 receptor 
was immunoprecipitated with an anti-FLAG M2 agarose beads, resolved by SDS-PAGE 
and detected by autoradiography (top panel) and an anti-FLAG antibody (bottom panel), 
respectively. (B) The relative levels of palmitoylation of each mutant compared to the 
wild-type LPA2 receptor after normalization by total receptor expression. 
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Figure 3.11.  2-bromopalmitate inhibits LPA2 palmitoylation. HEK 293T cells 
expressing FLAG-LPA2 was pretreated with 100 µM 2-BP for 30 min followed by the 
labeling with [
3
H] palmitic acid at 37 
o
C for 2 h. The FLAG-LPA2 receptor was 
immunoprecipitated with an anti-FLAG agarose beads, resolved by SDS-PAGE and 
detected by autoradiography (top panel) and an anti-FLAG antibody (bottom panel), 
respectively.   
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followed by the acyl-biotinyl exchange with hydroxylamine and biotin-HPDP. The 
biotinylated FLAG-LPA2 receptor was eluted from the beads using excess FLAG 
peptides for competition, and then precipitated with avidin beads. After SDS-PAGE, the 
immunoblot was probed with an anti-FLAG antibody to detect the palmitoylated FLAG-
LPA2 receptor. 2-BP caused no change in the amount of either Siva-1 or TRIP6 pull-
down by FLAG-LPA2 to vehicle, even though the palmitoylation of LPA2 was completely 
blocked by 2-BP at 4 h (Fig. 3.12). This suggests that palmitoylation in LPA2 does not 
interfere with the association of LPA2 with TRIP6 or Siva-1. These results expand our in 
vitro studies with the non-palmitoylated E. Coli-derived recombinant proteins that 
showed strong interactions between LPA2 and the LIM proteins.  
 
 
3.3.6 Characterization of Lentivirus-transduced Stable MEFs Expressing hLPA2 
WT and Mutants Defective in Interaction with PDZ or LIM Domain Proteins 
 
To examine the interaction in a physiological context and study the role of 
interaction of LPA2 with TRIP6 and Siva-1 and PDZ proteins in LPA2-mediated anti-
apoptosis, we generated stable cell lines expressing WT LPA2 and mutants in 
spontaneously immortalized DKO MEFs by lentiviral transduction (Fig. 3.13). The DKO 
MEFs provide a cell platform for the study of LPA2 function via reconstitution because 
these DKO MEFs only express LPA4 and LPA7 (p2y5) detected by real-time PCR but not 
the other EDG-family receptors (Fig. 3.14). Furthermore, DKO MEFs show no LPA-
induced Ca
2+
 mobilization, ERK1/2 or Akt phosphorylation in response to LPA 
stimulation (Contos, 2002 and our findings). In addition, the advantage of lentiviral 
transduction with the ability to control levels of expression near physiological level of the 
transduced gene by titration of the virus allows valid comparison between different lines 
expressing different constructs. The lentiviral constructs for mutants we generated 
included C311A/C314A, L351A and C311A/C314A/L351A. RT-PCR showed similar 
expression levels between different stable MEFs and the level is comparable to 
endogenous LPA2 expressed in WT MEFs. The parental as well as GFP-transduced DKO 
MEFS do not express LPA2 and served as negative controls (Fig.3.15A). Expression of 
receptor RNA constructs was confirmed by RT-PCR (Fig 3.15A) and quantitative real 
time PCR, which showed the similar expression of the receptors in mRNA (Fig 3.15B).  
Comparable receptor protein expression was demonstrated by immunoprecipitation-
immunoblotting (Fig 3.16A). Flow cytometry was carried out to examine cell surface 
expression of the receptor mutants. As shown in Fig 3.16B, the level of cell surface 
expression between these stable lines was highly comparable, indicating that these 
mutations did not affect receptor targeting to the plasma membrane in the DKO MEFs. 
 
LPA2 couples to Gq and Gi heterotrimeric G proteins, which both are involved in 
mediating LPA-induced Ca
2+
 mobilization. Ligand-induced Ca
2+
 mobilization assays 
showed that the maximal response to saturating LPA concentrations (Emax) and the half-
maximally effective concentration (EC50) were not different among these stable clonal 
lines and the WT LPA2 (Fig. 3.17). This indicates that the C-terminal mutations does not 
affect receptor coupling to Gq&i proteins when expressed in DKO MEFs. There was no 
detectable Ca
2+
 response in the non-transduced or mock-transduced DKO MEFs, which 
was consistent with a previous publication (Contos, 2002). 
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Figure 3.12.  Palmitoylation is not required for interaction of LPA2-CT with TRIP6 
or Siva-1. GFP-Siva-1 or GFP-TRIP6 was co-expressed with the FLAG-LPA2 receptor 
in HEK 293T cells. After treatment with 100 µM 2-BP in 0.1% BSA-containing DMEM 
for 4 h, cells were stimulated with LPA for 10 min, and the FLAG-LPA2 receptor was 
immunoprecipitated with the anti-FLAG antibody-conjugated agarose beads. Half of the 
precipitates were resolved by SDS-PAGE and the immunoblot was probed with an anti-
GFP polyclonal antibody to detect GFP-Siva-1 and GFP-TRIP6, respectively. The rest of 
the samples were subjected to acyl-biotinyl exchange procedure to determine the levels of 
palmitoylated LPA2 receptor. Briefly, the precipitated LPA2 receptor was pre-treated with 
NEM followed by the acyl-biotinyl exchange with hydroxylamine and biotin-HPDP. The 
biotinylated FLAG-LPA2 receptor was eluted from the beads using excess FLAG 
peptides for competition, and then precipitated with avidin beads. After SDS-PAGE, the 
immunoblot was probed with an anti-FLAG antibody to detect the palmitoylated FLAG-
LPA2 receptor.  
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Figure 3.13.  Schematic illustration of lentiviral LPA2 constructs. 
 
 
 
 
 
 
 
Figure 3.14.  mRNA expression profile of LPA receptors in spontaneously 
immortalized LPA1/2 DKO MEFs.  
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Figure 3.15.  mRNA expression of WT LPA2 and its mutants in lentivirus-
transduced DKO MEFs. Lentivirus carrying the FLAG-LPA2 receptor constructs with 
mutants C311A/C314A, L351A or C311A/C314A/L351A were stably transduced into 
DKO MEFs. The expression of LPA2 receptor mRNA was determined by semi-
quantitative RT-PCR analysis (A) and real-time PCR (B). 
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Figure 3.16.  Cellular protein and cell surface expression of WT LPA2 and its 
mutants in lentivirus-transduced DKO MEFs. Lentiviruses carrying the FLAG-LPA2 
receptor constructs with mutants C311A/C314A, L351A or C311A/C314A/L351A were 
stably transduced into DKO MEFs. (A) The LPA2 receptor protein in the whole cell 
lysates (1.2 mg) was determined by immunoprecipitation with the anti-FLAG M2 
antibody-conjugated agarose beads followed by immunoblotting with an anti-FLAG 
polyclonal antibody. (B) Cells were incubated on ice with an anti-FLAG M2 monoclonal 
antibody for 1h followed by the FITC-conjugated anti-mouse secondary antibody for 
another hour. After fixation, flow cytometry was performed to determine receptor 
expression. Data shown is the mean ± S.E. compared to the WT LPA2 levels in three 
independent experiments.  
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Figure 3.17.  Mutation of CxxC and/or PDZ motif(s) of LPA2-CT does not affect 
ligand-induced Ca
2+
 mobilization. The spontaneously immortalized DKO MEFs stably 
expressing mock, WT LPA2, LPA2-C311A/C314A, LPA2-L351A or LPA2-
C311A/C314A/L351A by lentiviral transduction were loaded with Fura-2/AM at 37 °C 
for 1 h and monitored in a FLEXstation at excitation wavelengths of 340/380 nm and 
emission wavelength of 510 nm for 70 sec after the addition of LPA 18:1 at 
concentrations indicated. The curves for WT LPA2 and mutants were generated by 
normalizing the Ca
2+
 peak at various dilutions to the response elicited by the highest 
concentration of LPA (1 µM) applied. The values of the mock-transduced MEFs were 
normalized to that of WT LPA2 -transduced MEFs. 
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Previously others and we have shown that ERK and Akt activation is required for 
the anti-apoptotic protection of LPA2 (E, 2007; Rusovici, 2007). We hypothesized that 
mutation of the LIM or PDZ interaction motif of LPA2 might affect antiapoptotic signals 
mediated thorugh these kinase pathways. We tested ERK1/2 and Akt activation in the 
lentivirus-transduced stable MEFs that express WT LPA2 and its mutants. As shown in 
Fig. 3.18, in mock transduced MEFs there was no detectable ERK1/2 phosphorylation by 
1 µM LPA treatment for 10 min. ERK1/2 activation was greatly reduced in 
C311A/C314A, and L351A mutant-expressing cells and almost completely abolished in 
the C311A/C314A/L351A mutant compared with WT LPA2. Similarly, the activation of 
Akt by 1 µM LPA treatment for 10 min showed the same pattern as LPA-induced 
ERK1/2 activation. These data indicate that disruption of LPA2 interaction with LIM or 
PDZ binding domain proteins attenuates ERK and Akt signaling, which are important for 
antiapoptotic signaling. 
 
 
3.3.7 LPA2-mediated Protection from DNA Damage-induced Apoptosis Is 
Regulated by the CxxC and PDZ-binding Motifs  
 
The finding of impaired ERK1/2 and Akt activation (Fig. 3.18) together with the 
role of LPA2 in mediating proapoptotic function of Siva-1 led us to hypothesize that 
disruption of LPA2 interaction with either the LIM binding or PDZ binding proteins will 
attenuate its antiapoptotic effect. To test the apoptotic properties of the LPA2 mutants 
expressed in DKO MEFs we performed Annexin V staining following the induction of 
apoptosis using 1.5 µM adriamycin for 14 h. Consistent with the alteration in ERK1/2 
and Akt signaling in the C311AC314A stable MEFs, apoptotic protection was impaired 
in MEFs expressing this mutant (Fig. 3.19). However, LPA still elicited significant 
protection against adriamycin-induced apoptosis in L351A MEFs, albeit to a reduced 
extent compared to WT LPA2. There was no protection in the MEF expressing the 
C311AC314AL351A mutant. These findings support the hypothesis for the role of these 
C terminal protein-protein interactions in antiapoptotic protection. 
  
To substantiate the finding with annexin V expression, we carried out DNA 
fragmentation assay in these MEF cell lines. To activate LPA2 we applied 1 !M LPA 1 h 
after adriamycin-induced activation of the intrinsic apoptotic pathway. LPA protected 2 
µM adriamycin-induced DNA fragmentation in stable lines expressing WT LPA2, and 
C311AC314A while not in mock, L351A or C311AC314AL351A-expressing lines (Fig. 
3.20). Thus DNA fragmentation assays confirmed that disruption of these protein-protein 
interactions abolishes the anti-apoptotic effect of LPA2. Of note, is that in the mock-
transduced MEFs, DNA fragmentation was high in the serum starvation group, indicating 
the protective effect of LPA2 against serum starvation-induced apoptosis.  
 
Several lines of evidence demonstrate that Siva-1-induced apoptosis is mediated 
by the mitochondrial pathway (Prasad 1997; Py, 2004; Chu 2004, 2005). Moreover, 
overexpression of Siva-1 promotes adriamycin-induced procaspase 3 cleavage, and this 
effect is reduced by LPA pretreatment (Lin, 2007). We hypothesized that Siva-1 levels in 
the cytoplasm and adriamycin-induced procaspase-3 cleavage will be affected in those 
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Figure 3.18.  Mutation of CxxC and/or PDZ motif(s) of LPA2-CT attenuates ERK1/2 
and Akt activation by LPA. The spontaneously immortalized DKO MEFs stably 
expressing GFP, WT LPA2, LPA2-C311A/C314A, LPA2-L351A or LPA2-
C311A/C314A/L351A and mock transduced by lentivirus were serum starved for 2.5 h in 
DMEM followed by stimulation with 1 µM LPA for 10 min. Cells were lyzed in SDS 
sample buffer and 15 µg of the lysate was loaded for phospho-ERK1/2 and 80 µg for 
phospho-Akt determination. The same blot was stripped and reprobed with mouse anti-
ERK1 and rabbit anti-Akt IgG, respectively. 
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Figure 3.19.  Mutation of CxxC and PDZ motifs of LPA2-CT abolishes protection 
against adriamycin-induced apoptosis revealed by Annexin V staining. Different 
MEF cell lines were pretreated with 10 !M LPA in 0.1% BSA-containing medium for 1 
or 2 h followed by the addition of 1.5 !M adriamycin for 14 h. Apoptosis was determined 
by Annexin V-FITC staining followed by flow cytometry analysis. Data shown is the 
mean ± S.E.M. of three independent experiments.   
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Figure 3.20.  Mutation of CxxC and PDZ motifs of LPA2-CT abolishes protection 
against adriamycin-induced apoptosis revealed by DNA fragmentation assay. 
Different MEF cell lines were treated with 2 !M adriamycin for 5.5 h.  Vehicle or 1 !M 
LPA in 0.5% BSA-containing medium were treated 1 h after addition of adriamycin. 
Apoptosis was determined by DNA fragmentation assay as described in Materials and 
Methods. Data shown is the mean ± S.E.M. of three independent experiments.   
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mutants with disrupted interaction of Siva-1 with LPA2. To test this hypothesis, we 
examined procaspase 3 cleavage in these stable MEF lines challenged with 1.5 µM 
adriamycin with or without 10 !M LPA. LPA reversed procaspase 3 cleavage induced by 
adriamycin in the LPA2 WT MEFs, which was not recapitulated in the mock, 
C311AC314A, and C311AC314AL351A expressing MEFs and much reduced in L351A 
MEFs, suggesting the role of both PDZ and LIM domain proteins in protecting from 
adriamycin-induced apoptosis (Fig. 3.21 top panel). 
 
We also examined Siva-1 protein expression in these MEFs in response to LPA. 
In WT LPA2 MEFs adriamycin-induced Siva-1 protein expression, which was attenuated 
by LPA treatment (Fig. 3.21 lower panel). In MEFs transduced with C311AC314A and 
C311AC314AL351A mutants LPA failed to reduce adriamycin-induced Siva-1 
expression. In the L351A MEFs the reduction in Siva-1 expression was detected, 
indicating PDZ protein binding is not involved in regulating Siva-1 protein level. 
 
 
3.4     DISCUSSION 
 
LPA is a phospholipid growth factor that elicits cellular responses via the 
activation of its cognate GPCRs. Recently, a number of scaffold proteins interacting with 
LPA2 C-terminal tail (CT) have been reported. These proteins mediate LPA signaling by 
protein-protein interactions different from the classical G-protein coupled pathways. The 
LIM domain proteins TRIP6 (Xu, 2004) and the proapoptotic molecule Siva-1 (Lin, 
2007) represent a new set of interacting proteins whose binding site has not yet been 
identified. In contrast, the interaction of LPA2-CT with the PDZ domain proteins 
 
 
 
 
 
Figure 3.21.  Mutation of CxxC and/or PDZ motif(s) of LPA2-CT abolishes 
protection against adriamycin-induced Caspase 3 activation and regulation of Siva-
1 expression. Different MEF cell lines were pretreated with 10 µM LPA in 0.1% BSA-
containing medium for 1 or 2 h followed by the addition of 1.5 µM adriamycin for 14 h. 
The expression of procaspase-3 and Siva-1 was detected by immunoblotting using the 
antibodies specific to caspase-3 and Siva-1, respectively. 
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including NHERF2, PDZ-RhoGEF, leukemia-associated RhoGEF, MAGI-3 (Oh, 2004; 
Wang, 2004; Yamada, 2005; Zhang, 2007) is much better understood in terms of the 
motifs that are required for this interaction as well as the physiological significance of the 
complex. Binding of LIM and PDZ domain proteins to the LPA2-CT also raises the 
question: is there competition or cooperativity between them? 
 
Here we report the identification of a TRIP6 and Siva-1 binding motif in LPA2-
CT: C
311
xxC
314
 (Fig.3.5 and Fig 3.9). Previously it has been shown that LPA2-CT 
interacts with aa278-476 constituting the third LIM domain TRIP6 (Xu, 2004) and the 
aa142-170 comprising the second zinc-finger domain of Siva-1 (Lin, 2007). The LIM 
domain consists of tandem zinc-finger motifs that are cysteine rich and capable of 
coordinating zinc (Dawid, 1998; Kadrmas & Beckerle, 2004 review). Based on this 
criterion, Siva-1 can be relegated to the LIM domain proteins because it has two 
sequential zinc-finger motifs at its CT. Once considered to be exclusively a DNA-binding 
motif, zinc-finger now has been demonstrated to be a protein recognition motif as well 
(Mackay 1998; Gamsjaeger, 2007). The LIM/double zinc finger motif functions as a 
homo and heterodimerization domain (Feuerstein, 1994; Schmeichel & Beckerle, 1994; 
Arber & Caroni, 1996). So far no discrete consensus binding sequence has been 
identified for LIM domain proteins. LIM domains recognize different target proteins in a 
variable manner (Velyvis, 2003).  
 
Although TRIP6 and Siva-1 bind to the same motif in LPA2-CT, the binding 
affinity appears to be stronger for Siva-1 than TRIP6. One possible explanation is that 
there is one more cysteine in the second zinc-finger motif of Siva-1 than that in LIM3 of 
TRIP6. This may correlate with their different way of association with LPA2. Siva-1 
binds to the internalized LPA2 and both end up in the proteasome for degradation, 
whereas the association of TRIP6 with LPA2 is transient since LPA2 is not at the focal 
adhesion plaque where TRIP6 localizes after LPA stimulation for 15-20 min (Xu, 2004; 
Lin, 2007; Lin, 2008 review). Intriguingly, the other EDG family receptors whose ligand 
is sphingosine-1-phosphate, S1P1 and S1P4 also contain the CxxC motifs at their CTs. 
Whether these receptors interact with LIM proteins remains to be determined.  
 
Cysteine residues in the C-termini of GPCR are targets for posttranslational 
modification by palmitoylation. Palmitoylation of the GPCRs plays important roles in 
receptor binding, targeting, trafficking, signaling and protein interactions (Qanbar & 
Bouvier, 2003 review; Resh, 2006 review; Escriba, 2007 review). In addition, 
palmitoylation of cys 261 in the Hepatitis C virus NS4B protein is important for the 
protein–protein interaction in the formation of the virus RNA replication complex (Yu, 
2006). Palmitoylation is required for postsynaptic density (PSD-95) protein 
multidimerization, postsynaptic targeting and clustering of glutamate receptors 
(Christopherson, 2003). We identified multiple palmitoylation sites in the LPA2-CT that 
included the CxxC motif. This raised the possibility that palmitoylation of these two 
cysteine residues involved in the interaction with LIM proteins might regulate their 
interaction. Our pull down experiments with recombinant LPA2-CT and the Siva-1 or 
TRIP6 showed that palmitoylation is not required for complex formation because E.Coli 
lacks Protein Acyl Transferases (PATs). However, when transfected into HEK-293 cells, 
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we found that the CxxC motif was palmitoylated but blocking palmitoylation of LPA2 did 
not affect its association with TRIP6 or Siva-1. Using the acyl-biotinyl exchange method 
we have also determined that in HEK293 cells TRIP6 forms a complex with 
palmitoylated CxxC motifs. In this procedure, the palmitoyl-cysteine is specificly 
biotinylated using hydroxylamine and biotin-HPDP. Coimmunoprecipitation of the 
TRIP6-LPA2 complex showed that the LPA2 present in this complex was palmitoylated 
because it was labeled with biotin during the acyl-biotin exchange chemistry (Fig. 3.12).  
These observations indicate that palmitoylation is not required for the interaction of the 
LIM domain protein TRIP6 and LPA2, discounting the role of palmitoylation-mediated 
regulation of their interacion.  
 
Previously we reported that LPA2 reconstitution into RH cells devoid of EDG 
family LPA receptors, but not LPA1 or LPA3, was capable of rescuing these cells from 
TNF#-induced apoptosis by OTP. In support of the essential role of LPA2, neither LPA 
nor OTP protected the intestinal mucosa of LPA2 knockout mice, whereas both ligands 
were active in LPA1 receptor knockouts (E, 2007). The activation of ERK and protective 
effect of OTP in LPA2-reconstituted RH that is partially sensitive to PTX indicate a role 
for non-Gi mediated signals. The antiapoptotic effect of OTP in LPA2-reconstituted RH 
cells could not be explained by Gq mediated signals because all three LPA receptors 
activate Gq-linked Ca
2+
 transients, yet only LPA2 was protective. In support of this, Yun 
and colleagues found that LPA protects Caco 2 cells, which predominately express LPA2, 
from etopside-induced apoptosis by activation of ERK and inactivation of Bad and 
caspase 3 in a PTX-insensitive, NHERF2-dependent manner (Yun, 2005; Rusovici, 
2007). These observations suggest G protein-independent signaling is involved in LPA2 -
mediated protection against apoptosis. We hypothesized that the protein-protein 
interactions mediated by the LPA2-CT play a role in this cellular response. 
 
Knockdown of the PDZ binding protein NHERF2 attenuates LPA-induced ERK 
and Akt and abrogates the protective effect of LPA2 in Caco-2 cells (Yun, 2005; 
Rusovici, 2007). MAGI-3 regulates LPA-dependent ERK and RhoA activation via 
interaction with LPA2 (Zhang, 2007). These reports taken together implicate the role of 
protein-protein interactions mediated via the PDZ interaction motif of LPA2 in 
antiapoptotic signaling. Similarly, LPA-induced ERK activation is strongly reduced by 
siRNA-mediated knockdown of TRIP6 (Lai, 2005), suggesting a role for a LIM protein 
in antiapoptotic signaling. Lai and colleagues showed that c-Src phosphorylates TRIP6 at 
Tyr55 and this phosphorylation enhances LPA-induced ERK activation. Knockdown of 
TRIP6 drastically attenuates LPA-induced ERK1/2 activation in c-Src expressing cells 
(Lai, 2005). In support of this, LPA activates c-Src (Luttrell, 1996; Kranenburg, 1997), 
and c-Src activity is required for the antiapoptotic effect of LPA and OTP (Deng & Tigyi 
- unpublished). LPA2 interacts with the proapoptotic transcription factor Siva-1 and LPA 
stimulation promotes the association of Siva-1 with LPA2 and targets the Siva-1-LPA2 
complex for ubiquitination and degradation (Lin, 2007). Siva-1 has been reported to form 
a complex with the antiapoptotic protein Bcl-XL, reducing its availability to protect 
mitochondrial outer membrane integrity (Xue, 2002; Chu, 2004). We found, in IEC-6 
(intestinal epithelial cells) and also in mice treated with OTP, that Bcl-XL levels did not 
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go down but increase (E, 2007). This could be due to LPA2-mediated degradation of 
Siva-1, which in turn would allow Bcl-XL to exert its protective action. 
 
Our results using LPA2 alanine mutants defective in interaction with either PDZ 
domain binding proteins (L351A) or with LIM domain proteins (C311AC314A) 
attenuated ERK and Akt phosphorylation by LPA in MEFs. Mutation of both domains in 
the C311AC314AL351A construct completely abolished the activation of ERK and Akt 
in MEFs (Fig.3.18). Consistent with this, the anti-apoptotic effect of LPA on adriamycin-
induced apoptosis, Siva-1 expression and procaspase 3 cleavage were severely 
compromised in the C311AC314AL351A mutant (Fig.3.19, Fig.3.20 and Fig.3.21). The 
L351A or C311AC314A mutant showed reduced protection that paralleled their 
attenuated activation of the LPA2 coupled prosurvival pathways. These results suggest 
cooperativity of PDZ and LIM proteins in mediating the LPA2 signaling. How is this 
cooperativity achieved? Our experiments showed that in the case of TRIP6, mutation of 
L351 to alanine reduced complex formation (Fig.3.3). PDZ domain binding proteins such 
as NHERF2 possess an N- and also a C-terminal PDZ binding domains. TRIP6, like 
LPA2, contains a C-terminal PDZ interaction motif. Taken together, the possibility exists 
that the complex of LPA2 with TRIP-6 is stabilized via a NHERF2 bridge engaging the 
PDZ motifs. Moreover, the ability of homodimerization of LPA2 and binding to TRIP6 
and/or Siva-1 provides much more flexibility for multi-protein complex formation 
(Bouvier, 2001). It has been proposed that proteins containing multiple LIM domains 
might function as a molecular bridge (Kadrmas & Beckerle, 2004 review). More work 
needs to be done to test this hypothesis and reveal the downstream signaling events 
initiated by protein-protein interaction with LPA2. 
 
Altogether, in this work we provide direct evidence, by using stable MEFs 
expressing comparable levels of LPA2 WT and mutants, that the protein-protein 
interaction between LPA2-CT with PDZ/TRIP6/Siva-1 mediates anti-apoptotic effects of 
LPA2 (Fig. 3.19, Fig.3.20, and Fig.3.21). The mutants defective in their interaction with 
LIM and PDZ binding proteins remain fully capable of activating G protein-coupled 
signals such as Ca
2+
 mobilization (Fig.3.17). The present findings expand the traditional 
view of G-protein coupling-mediated signaling of GPCRs and link it to direct pathways 
regulating a transcription factor Siva-1 and a scaffold protein TRIP6 (Fig. 3.22). 
Recently, inhibition of the protein-protein interaction with small-molecules is becoming 
an emerging area in drug discovery (Fry, 2006 & 2008 review). Hence, advances in 
understanding protein-protein interactions with LPA2 may provide the bases for 
discovering drugs that have therapeutic potential. 
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Figure 3.22.  Scheme of antiapoptotic mechanism of LPA2 by protein-protein 
interaction. DNA damage induces proapoptotic molecule Siva-1 expression and Siva-1 
binds to antiapoptotic protein Bcl-XL to induce apoptosis. Upon LPA stimulation, Siva-1, 
associating with LPA2 by CxxC motif, is targeted to proteasome for degradation, thereby 
no longer available to bind up Bcl-XL. In addition, TRIP6 and NHERF2 are recruited to 
the LPA2 by binding to CxxC and DSTL motifs, respectively, with LPA stimulation and 
NHERF2 also binds to TRIP6 via TTDC motif, forming a macromolecular complex. 
ERKs and Akt prosurvival pathways are activated and mediate the antiapoptotic effect. 
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